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L GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation consists of a literature review, three papers, a 
general summary, and an appendix. Paper three is to be submitted to the 
American Society for Microbiology publication. Journal of Clinical 
Microbiology, and is written in the appropriate format. Papers one sind 
two are to be submitted to the American Society for Microbiology 
publication. Infection and Immunity, and cire written in the 
corresponding format. The appendix contains data from two of the 
individual projects. Tables 1 through 18 from paper 1 (Chapter III) and 
Tables 19 through 31 from paper 2 (Chapter IV). 
Introduction 
Livestock producers have three major options in dealing with 
bacterial diseases affecting their herds: antibiotic therapy, vaccination 
and herd management practices. Antimicrobial drugs are used as 
therapies in outbreaks of bacterial diseases, as disease preventives and as 
growth promotants. Vaccination against disease causing organisms 
attempts to raise the herd immunity level to prevent infection, minimize 
clinical disease signs, and avert economic loss. All in - all out production, 
medicated early weaning and segregated early weaning are management 
procedures designed to reduce pathogenic organism trEmsmission. In 
practice, an acceptable combination of antimicrobials, vaccination and 
management can be used to maximize herd health and production. 
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The common mucosal immune system is responsible for immune 
defense functions on body mucous membranes such as the respiratory, 
reproductive and alimentary tracts and the surface of the eye. This 
system is stimulated by a distinctive antigen processing and presentation 
mechanism within these areas. 
Sufficient antibody titer, at or near respiratory mucosal surfaces, 
aids in preventing respiratory disease. Antibodies elicited by vaccination 
or exposure and distributed to body surfaces are important in protection 
against pathogens tr3ang to colonize mucosal surfaces. 
The objective of this project was to supply details importsint to 
defining the epidemiology of toxigenic PasteureUa multocida while 
exploring immune system enhancement as an aid in control. Class 
specific antibody titer in sera and on the nasal mucosa was measured to 
see If it would be affected by intramuscular injection of a toxigenic P. 
multocida combination bacterin/toxoid. The use of beta-hydroxy 
beta-methyl butyrate as an adjunct to vaccination was investigated. The 
local antibody response to respiratory infection and its usefulness as an 
indication of pathogen transmission among pigs was studied. Finadly, 
restriction endonuclease digestion was used to confirm organism 
identification in transmission studies among cohort pigs. 
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n. LITERATURE REVIEW 
Progressive Atrophic Rhinitis 
Introduction 
Atrophic rhinitis, as a clinical s)nidrome, was first described in pigs 
in 1830 (40). The condition has been attributed to many causes, both 
noninfectious and infectious. Due to the involvement of the nasal bony 
structures, atrophic rhinitis was once thought to be caused by a 
nutritional imbalance, specifically an inappropriate calcium to 
phosphorous ratio in swine feeds (23). Because of breed predilections for 
the condition, genetic influences have been proposed (158). 
Environmental conditions have been implicated when other causes could 
not be identified (10, 161). Studies reported in the 1940s attributed the 
disease to an infectious etiology (134) and this remains the focus of 
research today. 
Definition 
While recognizing the importance and contribution of adequate 
nutrition, soimd genetic background and environmental effects in the 
development of atrophic rhinitis, current research on the syndrome has 
focused specifically on the role of toxigenic Pasteurella multocida. This 
bacterium causes a swine upper respiratory disease characterized, 
clinically, by shortening or distortion of the snout, sneezing, nasal 
discharge and epistaxis. Hypoplasia of the nasal turbinate bones (conchsd 
atrophy) is the characteristic lesion (40). Petersen et al. suggested the 
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term Progressive Atrophic Rhinitis (PAR) to describe the disease 
syndrome caused by capsular types A or D toxigenic P. multocidcL Their 
proposal further defines PAR as a disease in which the resulting turbinate 
atrophy persists after the first weeks of life. Conversely, Non-progressive 
Atrophic Rhinitis, caused by BordeteUa bronchiseptica, causes turbinate 
atrophy early in life, with lesions regressing over time as heeding occurs 
(129, 149). 
Discovery of clinical signs or identification of conchal atrophy 
during slaughter examination with isolation of toxigenic P. multocida 
supports a clinical diagnosis of PAR. Subclinical forms of PAR are 
possible. Without external physical PAR signs, the producer may not be 
aware of subclinical infections. In moderate to severe cases however, the 
occurrence of lesions has been associated with reduced growth rates 
(40). 
When either turbinate atrophy is described but P. multocida is not 
recovered, or toxigenic P. multocida is recovered but turbinate atrophy is 
absent, a PAR diagnosis is questionable. In the first case, turbinate 
damage may have occurred due to a subsequently cleared infection. The 
Missouri Veterinary Diagnostic Laboratory reports recovering P. 
multocida from only 30% of submissions in which PAR lesions were found 
(163). The second case may be from em aborted or limited infection 
without enough time for PAR lesion to result. 
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Prevalence 
PAR prevalence in the nation's swine population is primarily found 
by clinical observations or by examination of snouts at slaughter, followed 
by bacterial culture. It has been estimated that 5% of the sow population 
carries toxigenic P. multocida without previous history of the disease. In 
cases of a low level of clinical signs, 10% prevalence has been estimated 
(27). A retrospective study done at the Missouri State Veterinary 
Diagnostic Laboratory foimd atrophic rhinitis in 27% of the necropsies 
done over a year's time (163). Slaughter examinations have led to 
estimations of 70% of market age swine showing signs of turbinate 
atrophy (115). Wilson et al., who sampled 1425 pigs from 27 randomly 
selected herds during summer and winter slaughter periods, found 60% 
of the pigs siffected with atrophic rhinitis (174). 
It may be possible for a swine herd to be P. multocida negative or 
have a herd prevgJence so low the organism is not recoverable. Nine 
percent of 102 Iowa herds cultured positive for the organism, but toxin 
production was not determined (75). 
When P. multocida is isolated from pigs, nontoxigenic strains are 
foimd more commonly than toxigenic strains. Forty-four percent of 163 
pigs from nine farrow to finish herds cultured positive for nontoxigenic P. 
multocida, while only 4% harbored the toxigenic strain (37). Nasal and 
tonsil swabs from 468 piglets, of 30 fsirms, jaelded nontoxigenic P. 
multocida from 24.7% of the tonsils and 18% of the nasal swabs without 
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toxigenic strains being recovered (15). The wide variation in toxigenic 
vs. nontoxigenic recovery rates has yet to be adequately explained. 
PAR and Production 
Introduction 
Extensive data have been collected regarding relationships between 
PAR and production parameters such as average daily gain (ADG). PAR 
and pneumonic lesions, and pneumonic lesions and ADG. There are 
convincing, yet at times conflicting, data describing these relationships. 
Evidence of a P. multocida effect on weight gain has been shown by 
Varga et al. (168). During antibiotic treatment based on sensitivity 
patterns of isolated B. bronchiseptica and P. multocida from pigs, treated 
animals showed a 19% improvement over control animals in feed 
conversion. This study also found commercial herds medicated with 
antibiotics eis young pigs had a 15.3% feed efiBciency improvement and a 
16% ADG improvement were foimd when P. multocida was not culturable 
from the nas£d cavity through the end of the 42 day treatment period. 
Nimierous experiments have directly supported the claim that 
lesions of PAR are signific2intly correlated with weight gain and/or feed 
efficiency during the growing and finishing periods (9, 10, 11, 12, 38, 
170, 174). Other experiments have arrived at equivocal results, with 
negative correlations between PAR and ADG being significant tn only 
sections of some studies (14, 120, 130). 
There are also those who contend PAR lesions present at slaughter 
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are not indicative of decreased production pgurameters. Straw et al. (158, 
159), Martineau et al. (104) and Love et al. (100), found no correlation 
between severity of turbinate atrophy and growth rate. 
Toxigenic P. nwltocida toxin 
The specific cause of a negative correlation between PAR £ind feed 
efficiency or ADG is not yet well defined, although P. multocida toxin has 
been incriminated. Cheville et al. saw severe systemic effects including 
hepatic necrosis, degenerated enterocytes in the gut lumen, kidney 
necrosis, edema in alveolar walls and necrosis of capillaries at 
cartilage-bone junctions when only 0.1 mg of toxin was given 
subcutaneously to pigs (32). Toxigenic P. multocida growth on a single 
horse blood agar plate can produce 15 to 30 mg of toxin (115). 
Finding generalized systemic lesions led to Investigations of the 
role absorption of P. multocida toxin may play in Eiffecting production 
parameters. Love et al. (100), Frymus et al. (61) and Chanter and Rutter 
(27) theorized the systemic effects of locally produced toxin associated 
with PAR might decrease feed intake, contributing to lower weight gains. 
A depression in growth rate may result from a general toxic influence of 
P. multocida toxin, rather than from turbinate atrophy. 
Goshal et al. investigated the effect of P. multocida toxin on porcine 
growth hormone level and actions (67). Porcine growth hormone 
concentrations in the plasma of naturally infected PAR pigs and healthy 
pigs were found to be similar. Decreases in growth rate of pigs with PAR, 
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they hj^othesized, may be because P. rmdtocida toxin affects the signal 
transduction pathway that is associated with the porcine growth hormone 
receptor complex. 
Pmstaglandin 
Pedersen and Elling, in studying the pathogenesis of PAR, 
speculated on the role of prostaglandins in the disease (128). Endotoxin 
likely contributes to the pathogenic potential of P. midtocida by activation 
of host defense systems, including the production and release of 
prostaglandins. Prostaglandin effects contribute to clinical signs and 
tissue damage. They also have negative effects on feed intake eind feed 
conversion (53). 
One attempt at proving this theory involved pretreatment of pigs 
with prostaglandin sjnithetase, a prostaglandin inhibitor. Pretreatment 
did not limit skin lesions or dermonecrosis following intradermal 
injection of P. midtocida toxin, however it is practicedly impossible to 
reach pharmacological concentrations of prostaglandin sjnithetase in 
tissues without killing the animals (53) 
Immiuwregulators 
Immunoregulators such as interleukins, tumor necrosis factor 
(TNF) and interferon cire found in the brain and cerebrospinal fluid 
during acute sind chronic pathologic processes, such as those occurring 
with PAR (138). Considered to be endogenous mediators of the 
inflammatory acute phase response, they may cause inappetence, fever 
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and somnolence (95, 138). TNF, Interlenkin-1 and alpha and gamma 
interferon have reduced food intake after parenteral administration in 
anim£ds (95). Fantino and Wieteska showed a reduction in food intake in 
rats due to direct TNF action on the central nervous system (52). 
PAR and pneumonia 
V/ith conflicting evidence regarding the correlation of turbinate 
pathology (snout scores) on daily gain, the question becomes whether 
turbinate atrophy is an inconsistent sign of some other condition that 
affects gain. One theory is that turbinate atrophy may be present when 
lung lesions develop, but it is the lung lesions that are responsible for 
decreased growth and gain. Cowart et al. examined at slaughter 163 pigs 
from nine herds and found a positive association between atrophic 
rhinitis scores and the development and extent of lung lesions (37). 
Straw estimated a 3.3% daily gain reduction for every 10% of the lung 
mass with pneumonic lesions (159). It would follow PAR, by decreasing 
the filtering capacity of the nasal passages, can affect the incidence and 
severity of pneumonia, which in turn can affect production and growth. 
Lack of correlation between PAR and growth may be due to management 
factors decreasing lung involvement, even with PAR present in the herd. 
The relationships among rhinitis, pneimionic lesions and 
production can also be disputed, however. Various studies have 
contradicted the theory of a positive relationship between snout scores 
and lung lesion development (64, 153, 158, 159, 174). Low correlation 
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coefiBcients between individual pig lung and snout scores show rhinitis 
playing onty a minor role in susceptibility to pneumonic lesions. A key 
may be that each of these studies examined the relationship between 
snout scores and lung lesions in individual pigs. Wilson et al. examined 
1,425 pigs from 27 different herds spanning seasonal marketing periods 
and foimd atrophic rhinitis and pneumonic lesions were poorly related in 
individual pigs. When the herd, rather than individuals were examined, 
however, there was a significantly positive correlation (174). 
Ekxmomics of PAR 
Although the direct effects PAR has on growth are the subject of 
considerable debate, there is little doubt in today's swine industiy that it 
is an economically important disease. In Iowa, it is estimated $111.86 
per 1000 swine per month (approximately $166,000.00 per month) has 
been spent on PAR prevention or treatment costs (85). This is a 
substantial resource allotment for a disease in which research on 
production parameter effects is not unified. 
When estimating a 6.7% (115) to 16% (168) reduction in average 
daily gain in affected pigs, the total cost of this disease increases 
dramatically. A 7% reduction in average daily gain results in at least ten 
extra days on feed to reach marketable weight (115). Estimating an 
increased cost of $2.46 to produce one marketable hog, PAR costs the 
United States swine industry as much as $203 million per year (115). 
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Clinical PAR 
Diagnosis 
PAR diagnosis is achieved by demonstration of nasal turbinate 
atrophy with isolation of toxigenic P. multocida. Although it is possible to 
have turbinate lesions without isolation, and isolation without lesions, a 
definitive diagnosis of PAR requires meeting both criteria. Techniques 
used for sample collection, bacterial isolation and turbinate evaluation will 
affect diagnosis and are therefore important. 
Sample collection The most common live animal sample 
collection method involves passing a swab deep into the nasal cavity to 
wipe the nasal turbinate. While inexpensive and easily performed in the 
field, there could be concern clinically relevant isolations may be missed 
because of limited semipling area. 
Although not easily applicable in field situations, nasal lavage 
increases the likelihood of sampling the entire nasal cavity. A problem 
cirises in deciding what fluid and recovery method to use. Twenty 
milliliters of phosphate buffered saline has been instilled in one nostril of 
dorsally recumbent pigs sind collected fi-om the other. This method was 
reportedly more sensitive for detecting infected pigs than nassd swabbing 
(120). The exact site of sampling was not addressed, however. No direct 
swabbing of the tonsils and oropharyngeal region was included and it is 
possible flushing in this way could have resulted in sampling the 
oropharyngeal region, besides the nasal cavity. 
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Sample handling Handling of the collected samples is also an 
important consideration. During a study designed to evaluate sampling 
and processing procedures, it was found direct selective media 
inoculation from cotton swabs the same day as collection was the most 
reliable culture recovery method. Placing the samples in transport 
media, before culturing on selective media or by mouse intraperitoneal 
injection, decreased the percent positive swabs (28). 
Media The media used for culture should also be considered. 
Colimibia blood agar base with neomycin and bacitracin added is more 
effective in P. multocida isolation than 4% sheep blood agar, when gross 
colony characteristics are used for preliminary identification (77, 78). P. 
multocida isolation has been enhetnced by intraperitonesil injection of 
mice with fluid from nasal swab samples suspended in sterile saline (41). 
This technique, sdthough very sensitive, is time consimriing, raises the 
issue of emimal welfare and cannot differentiate toxigenic from 
nontoxigenic strains. It is also possible nontoxigenic strains could 
flourish and overgrow toxigenic strains or cause death of the mouse 
before toxigenic strains reach recoverable numbers (27). 
In one study, P. multocida was recovered intermittently during the 
first week after inoculation in pigs already B. bronchiseptica culture 
positive. Only one pig remained consistently culture positive during the 
six week test period, while P. multocida was recovered sporadically from 
the other exposed pigs (77). This type of irregular recovery pattern was 
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also seen during a field study in which sequential nasal swabs were 
collected firom pigs on 8 Iowa farrow to finish swine operations. 
Sampling was done at 1, 3, 6 and 12 weeks of age, on each of four pigs, in 
five different litters firom the farms. Of 80 P. multocida isolations, 14 
were toxigenic. All 14 came firom three of the eight farms during various 
weeks of sampling (78). 
Slaughter check Examination of tlie cut surface of the snout at 
slaughter (slaughter check) is the usual method for finding the gross 
lesions of PAR. Commonly, the slaughter check is also used to evaluate 
the lungs for presence or degree of pneumonia, along with other health 
related parameters. 
Clinical PAR is confirmed by post mortem examination of a snout 
transverse section at the level of the first or second premolar tooth (44, 
105). The greatest space, in millimeters, is measured between the 
ventral turbinate scroll and the ventral/lateral nasal bone. Consistently 
sectioning at this site allows interanimal and interherd comparisons, 
because a natural widening of the space surrounding turbinates occurs as 
they course through the nasal cavity. 
Vcirious scoring systems have been used to quantify turbinate 
atrophy. A numeric grading system that describes the degree of atrophy 
and takes into accoimt deviation of the nasal septum, if present, is 
commonly used (14, 44). 
More recently, photographing the sectioned snout, followed by 
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computer analysis of the degree of atrophy, has been described (35, 44). 
The linear perimeter of the area occupied by the turbinate is measured, 
as is the linear perimeter of the inside border of the nostril. These 
values are compared by ratio, describing the relationship of the area 
occupied by the turbinate to the total area available. This computerized 
tomography technique is useful for diagnosing PAR and, while comparable 
to visual post mortem grading systems, is less subjective (87, 130). When 
correlating production parameters such as average daily gain with degree 
of PAR, the computerized tomography is more accurate than visual 
measurement (130). 
Factors affecting slaughter checks Additional factors influencing 
the validity of the slaughter check to imply herd PAR status need to be 
considered. Because positive culture and gross lesions defiae PAR, the 
likelihood of a false positive from a slaughter check is low. A false 
negative conclusion, however, is possible if gross lesions aren't 
recognized or toxigenic P. multocida is not isolated. 
Sample size Slaughter check sample size must be adequate 
to provide a satisfactory probability PAR can be detected, or prevalence 
estimated, within a herd. Sampling sdl the animals in the herd or group 
would establish both the presence and prevalence of PAR but, without a 
whole herd test, at least a statistically based sample size should be used. 
The appropriate s£imple size is based on the probability level of a 
fsdse negative result one is willing to allow and the actual or estimated 
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prevalence of the disease within the population. The equation used for 
deciding the number of animals needed for detection of a disease is: 
log Pb 
" "" logd-P)  
This is where n = appropriate sstmple size needed to detect a condition 
within a herd of infinite population size; Pb = the probability of a false 
negative result (as a decimal); and P = actual or estimated prevalence of 
the condition within the entire population (155). As one is willing to 
accept greater risk of a false negative result, or the prevalence within the 
herd increases, the number of animals needed to be sampled for 
detection will decrease. 
Sample size determining prevalence is different from sample size 
for detection. A sample size appropriate for a population of infinite size is 
calculated by: 
(P)(1-P)(Z2) 
pop- ^2 
Ninf pop is the sample nimiber needed given a population of infinite 
number, when P = the estimated prevalence expressed as a decimal, Z = 
degree of confidence in the estimate (refer to Table 1) and d = the 
^inf 
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Table I. Values for setting sample size (155) 
Decree of Confidence in Estimate Value of Z 
99% 2.58 
95% 1.96 
90% 1.64 
80% 1.28 
50% 0.674 
maximum difference between t±ie observed prevalence and tJie true 
prevalence one is willing to accept (expressed as a decimal). 
A sample size to discover prevalence within a defined population 
size can then be found by the equation: 
Nfi = P°P 
"f lnpop (Ninfpop- l )  
N 
where Ngn pop = number needed to sample given a specific 
population size, Njuf pop = the number needed to sample given a 
population of infinite number and N = the number in the finite population 
(155). Without sound statistical methods erroneous assumptions 
regarding the herd PAR status may result. 
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Seasonal variation Seasonal variation of slaughter check 
results in an individual swine operation can occm-. Higher PAR scores 
and depressed growth indicators have been associated with pigs farrowed 
in winter months and marketed in the summer (153, 154). Slaughter 
check interpretation is most accurate when seasonal effects are taken 
into consideration. 
Production stage A caution regarding slaughter check 
results comes from Scheit's work in Indiana. In his ansdysis, lung lesion 
scores did not significantly correlate with growth indicators during any 
season (152). The lack of significant correlation between lung lesion 
scores and growth indicators could be explained if gross pneumonic 
lesions are able to resolve within a certain period (153). It would follow 
this may also explain a lack of correlation between PAR and lung lesion 
scores. Slaughter checks are an examination at one point in time and 
may not represent the herd status at different production stages. 
Seroloau An adjunct to the direct diagnosis of PAR by positive 
culture and lesion detection is serological testing. Specific anti-P. 
multocida toxin antibody present in the sera of non-vaccinated pigs is 
evidence of at least exposure to a toxigenic P. multocida. 
Enzyme linked immunoassay Previous serological tests 
were based on detection of antibodies to epitopes on or within the whole 
P. multocida cell. As such, these tests were confounded by lack of 
specificity due to cross reactions with bacteria that share common 
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antigens. The inability to identify a toxigenic strain unique antigen meant 
seroconversion could have resulted from exposure to nontoxigenic strains 
or other closely related non-Pasteurella bacteria. Given the ubiquitous 
nature of Pasteurella species, seroconversion to shared antigens made 
specific serologic diagnosis impossible. 
Foged et al. have developed an enzyme linked immimosorbant assay 
(ELISA) using specific monoclonal anti-P. multocida toxin antibodies. 
This ELISA detects presence of the dermonecrotic toxin produced 
specifically by toxigenic P. multocida (58, 170), solving the problem of 
serologic cross reactions with nontoxigenic strains and related bacteria. 
Modification of the ELISA procedure allows detection of antl-P. multocida 
toxin antibodies in serum or body secretions (57, 122). Thus, it is 
possible to show seroconversion to the toxin, impljring exposure, even 
without isolation of the toxigenic organism. 
Seroconversion Toxigenic P. multocida infection, if 
localized in the upper respiratory passages, inconsistently results in 
seroconversion (61, 147). Localization of the infection on the nasal 
passage surface may allow the toxin to exert its effects on the nasal 
conchae without systemic immime system exposure. Alternatively, 
Chanter and Rutter suggest the lack of seroconversion may be due to a 
deficiency in the nasal cavity immune mechanisms, possibly toxin 
induced, or poor toxin immunogenlclty when in the presence of other 
antigens (27). 
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Control of PAR 
Transmission 
Once PAR was established as a condition caused by an infectious 
organism, the study of transmission became important in addressing 
control and eradication. Initially much of the work was centered on B. 
bronchiseptica. Recent emphasis has shifted to P. multocida, specifically 
toxigenic strains. 
Because nontoxigenic strains are firequently isolated firom clinically 
normal animals, it is thought P. multocida exists as a normal resident on 
the nasal mucosa of healthy pigs (118). Nontoxigenic and toxigenic 
strains have been isolated firom grossly normal snout and lung samples at 
slaughter (79). 
Nielsen et al. concluded intermittent success in recovering the 
organism fi-om inoculated pigs meant the infection in the nasal cavity is 
probably short lived (120). Continued transmission between infected and 
noninfected pigs must then occur to maintaiin the organism within the 
population (15, 37, 118). Housing pigs from a PAR herd with pigs 
without history of the condition resulted in PAR and isolation of both 
toxigenic and nontoxigenic strains firom both groups (8). 
The age of susceptibility to transmission is an additional factor that 
must be addressed to fully understand the epidemiology of the organism. 
Horizontal transmission (pig to pig) is different firom vertical 
transmission (sow to offspring). An understanding of the relative 
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importance of the two is necessary to design effective intervention 
strategies. 
It was once assumed infection in piglets occurred within the first 
weeks of life (145). However, moving gilts from a herd of origin with 
minimal PAR to an isolated site with optimal environmental conditions 
does not affect PAR prevalence in the offspring (10). Vertical 
transmission occurs even with ideal cleanliness and air quality. Direct 
nose to nose contact between the sow and her offspring apparently can 
lead to transmission (10). 
Horizontal transmission was shown among pigs in a study by 
Nielsen et al. Toxigenic P. multocida was isolated from 8% of a 
population when the pigs were 77 days of age or younger. After 77 days 
of age, 19% of the population was positive for toxigenic strains in nasal 
cavity, tonsil or lung samples. Transmission had occurred after the pigs 
left an all-in-all-out facility in which they were housed between 42 and 77 
days of age (120). 
Capsular serotyping and endonuclease digestion are tools used to 
better define the period of transmission. Oropharyngeal sampling of sows 
and offspring, and repeating the offspring sampling at 8 to 12 weeks and 
again at slaughter, uncovered no vertical transmission in a continuous 
flow farrow to finish operation. Horizontal transmission occurred 
between weaning and slaughter age (178). 
Uhlenhopp et al. showed vertical transmission in a naturally 
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infected farrow-to-finish herd. Post-weaning horizontal transmission 
then increased the number of culture positive offspring (164). 
In simamary, vertical transmission occurs early in life but the 
primary opportunity for spread is horizontal, post-weaning during 
grouping and regrouping of pigs as they grow. Either sows or finishing 
pigs would be the most reliable animals to swab when seeking the 
organism in apparently iminfected herds (70). 
Management 
Elicis' study of PAR found an increase in incidence could be 
attributed to either the introduction of new toxigenic strains or a 
breakdown in sound management practices (47). A PAR outbreak could 
be blamed on introduction of new toxigenic P. multocida, if new stock 
were added to the herd and there was a change in the capsular antigenic 
composition, virulence, or toxin production. Should the strains isolated 
during an outbreak not differ antigenicaUy firom previous isolates, but 
show an increase in virulence, management factors could be 
incriminated. 
In clinical situations, the incidence of PAR is most probably due to 
an interaction among many factors. Gardner et al. foiind the introduction 
of more than 50 pigs into the herd, despite the number of sources firom 
which they came, was a significsint PAR risk factor. Not included as risk 
factors were lack of herd replacement quarantine, antibiotic treatment 
and herd size (63). Because many factors may be involved (Table 2), with 
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Table 2. Factors thought to contribute to PAR. 
• Presence of other pathogens (71) 
• Poor management conditions/hygiene (27, 71) 
• Poor ventilation (27) 
• Overstocking/overcrowding (27, 69, 71) 
• Movement of pigs between groups (69, 71) 
• High dust levels (69) 
• Immunological factors (69) 
their definition and contribution subject to interpretation, the interaction 
between the environment and the pig's health might explain conflicting 
results concerning the PAR effect on rate of gain (10). 
Environment 
Air quality is a factor that is consistently associated with PAR. Mean 
snout scores, and percentage of snouts with a score of three or greater, 
from 1,117 pigs and 12 farms were significantly correlated with total air 
bacteria coimts, particle size and ammonia concentration (113). It is 
thought the mass or nimiber of particles present as inspirable aerosols or 
a large ntimber of viable bacteria may compromise the local defense 
mechEinisms of the upper respiratory tract, helping colonization of B. 
bronchiseptica and P. multocida (142). 
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Opportunity for continued exposure is another factor that may 
contribute to PAR. Housing various age groups (sows, weaners, growers 
and finishers) in the same shed aids in bacterial transmission and 
exposure (63). 
Seasonal effects highlight the relationship between the infectious 
and the environmental components leading to PAR Schwartz and 
Williams examined slaughter pigs over a four year period and foimd 
consistently higher PAR scores in those pigs farrowed in the winter and 
marketed in the summer (154). In examining the effect on ADG, Scheit 
et al. found as snout lesions become more severe, ADG decreased, but 
only for those pigs grown during the winter season (153). Even though 
air quality parameters were not directly measured in these two studies, 
they provide circumstantial evidence of an interaction between 
environmental factors and production effects of PAR 
While recognizing the importance of ventilation, Thomsen et al. 
implicated intensive pig unit stocking as a factor resulting in infection 
spreading by aerosol (161). Although the bacteriima quickly loses viability 
when aerosolized, under conditions of high humidity (more than or equal 
to 79% relative humidity) P. multocida remains infectious much longer 
(161). Overcrowding, especially during the winter season when 
ventilation may be poor, makes reaching a sustaining humidity level 
possible. Poor survival in other liquids suggests routes of transmission 
other than direct exposure are unlikely. Nose to nose contact or 
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exposing tonsils by eating nasal mucus contaminated fomites are the most 
probable transmission routes. 
Further support for environmental importance is provided by 
Wilson et al. When looking at herd data, rather than individual data, they 
found increased herd average lung scores and average snout scores were 
both correlated with decreased space per feeder pig (174). 
Vaccination 
Vaccination during various stages of production can help control 
PAR. It is important for the pork producer to remember vaccination is 
only one part of a PAR control program and, by itself, may fail if attention 
is not given to other management and environmental factors. 
Chanter and Rutter contend there has been no fruitful effort at 
reducing colonization by enhancing antibacterial immunity (27). Baalsrud 
supported this view by vaccinating pigs with a B. bronchiseptica and P. 
multocida bacterin and failing to show a signific8int reduction in PAR 
scores or increase in ADG (7). Rutter used a toxoid preparation in a 
vaccination schedule without affecting colonization in gnotobiotic pigs 
(144). 
Toxoids Conceding that vaccination with bacterins alone may not 
affect growth parameters or colonization, work by investigators in Europe 
emphasizes the importance of a vaccine toxoid component. From his 
work on the development of a recombinant P. multocida toxoid and the 
ELISA for detecting toxin production, Foged theorized toxoid vaccination 
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failure may be due to the method of toxoid production (17). Inconsistent 
vaccination effects result if the production process destroys important 
immunogenic epitopes and there is no consistent reproducible way to 
standardize antigenic vaccine load (36). The work of Diemen, et al., even 
questions the value of a toxoid, suggesting that in vivo protective immune 
response is not directed toward PMT but to an unidentified bacterisd 
component (166). 
By showing a reduction in the frequency and severity of turbinate 
lesions (18, 88, 127, 133) and successfully affecting production 
parameters and colonization (18, 121), a toxoid could be part of a 
successful vaccination program. Immunization of pregnant sows helps 
protective levels of antibodies to be passively transferred to their 
offspring. Measurable antitoxin titers persist up to eight weeks of age in 
the offspring (93) and antitoxin titer may be a crucial factor in protection 
ag£iinst PAR (121). 
Other management practices 
Antibiotic use Other management practices controlling PAR may 
include antibiotic treatments. Oxytetracycline, given either alone (68) or 
at the time of administering commercial toxoids (130), has been 
successful in reducing PAR lesions. 
Isolated site production Geiger et al. recently eradicated PAR 
from a persistently naturally infected herd showing clinical signs by using 
a three site production system (66). Table 3 outlines the pig movement 
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and antibiotic protocol used in this investigation. Comparing the snout 
scores of the isolated and medicated treatment group with the 
control group left at Site I, the protocol was successful in eliminating 
PAR lesions. Toxigenic P. multocida was not recovered from the control 
pigs though they exhibited typical PAR lesions. This may, however, have 
been due to sampling too few control pigs to reliably detect infection. 
Table 3. Protocol of isolated site PAR eradication (66). 
Site I 
CeftiofLir to sows prefarrowing. Ceftiofur to pigs at 1, 5 and 7 to 
10 days of age. Wean and move to site II at 7 to 10 days of age. 
Siten 
Ceftiofur to pigs at 12-15 days of age (5 days post-weaning). 
Sitem 
Arrive at 10-12 weeks of age. No further medication before 
slaughter. 
Eradication 
Once epidemiological questions such as method and age of 
trEinsmission and prevalence within different age groups have been 
investigated, scientifically based programs can be formed to control or 
eradicate PAR (70). The Netherlands began an eradication program in 
1958 (39). Initially voluntary, in 1980 the government began a 
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concentrated educational and financial effort to help pork producers with 
problems and questions regarding medication, vaccination, housing, 
ventilation and management. Although not yet complete, the eradication 
program has been successful in increasing the percentage of herds 
producing PAR free piglets from 5% to 64%. Percentage of herds with 
severe rhinitis problems dropped from 46% to 5% (39). These 
successes sire due to attention being paid to all facets of the swine 
operation diiring the program, underscoring the need to address a variety 
of management and herd health issues to control PAR. 
Pasteurella multocida 
Bacterici charcucteristics 
PasteweUa multocida is a bacterium in the family Pasteurellaceae 
and was named for Louis Pasteur, in honor of his work with the bacteria 
in avian species. The type species for the genus is P. multocida as named 
by Rosenbusch and Merchant in 1939 (103). 
Morvholoau P. multocida was first isolated and described by 
Toussaint in 1879 (141). It is a Gram-negative nonmotile 
nonsporogenous coccobacillus or short rod. Virulent strains Eire usually 
encapsulated (141). Bipolar staining is common, especially in 
preparations made from infected animal tissues (103). 
Growth The bacteriimi is a facultative anaerobe (103) that grows 
best in air or air plus 5% CO^ (141). Colonies incubated for 18-24 hours, 
aerobically, at 35-37° C on enriched media such as serum, blood, or 
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dextrose starch agars are typically 1-3 mm in diameter. They are mucoid 
or smooth and infrequently rough. Colonies of capsulated cells display a 
yellowish-green, bluish-green or peeirl-like iridescence (141). 
Table 4 lists the growth characteristics and biochemical reactions 
commonly used to identify the species. 
Differentiattna isolates P. midtocidn. has been the subject of 
extensive antigenic testing. Serologic typing has been used to study the 
epidemiology of the bacteria in many species (103). Carter, in 1955, 
identified by passive hemagglutination four capsular types, designated A, 
B, C and D (25). Type C was subsequently discarded and type E was 
added to describe antigenically distinct serotypes (103). Heddleston et 
al. used antisera produced in chickens and antigen from heated cells for a 
gel diffusion precipitin test to establish the existence of 16 distinct 
somatic or O group serovars (103, 141). 
Recently, additional techniques have been used to help further 
differentiate isolates. Electrophoresis of cell envelope proteins and 
lipopolysaccharide has shown the patterns of these cell components are 
conserved between P. nudtocida isolates (101). Restriction endonuclease 
cmalysis (REA) can also differentiate P. multocida isolates. Restriction 
endonucleases Hhal and Hpall have been used to study prevalence and 
transmission within and between swine herds (74, 82, 173, 177, 178). 
This technique has even provided evidence of a single source of 
29 
Table 4. Growth characteristics and biochemical reactions of 
PasteureUa midtocida (73, 103) 
Charactoistic Result 
3 hemolysis on blood agar _a 
Growth on Mac Conkey's agar -
Indole production 4.b 
Catalase activity + 
Oxidase activity (Kovac's) [+1^ 
Indole production + 
Urease activity + 
Gas from carbohydrates -
Acid production 
glucose + 
lactose -
mannitol + 
galactose + 
inositol 
^all strains negative 
^all strains positive 
'^most strains positive 
^ost strains negative 
30 
transmission into the swine herds of Australia (65). Using REIA, isolates 
of like somatic and capsular types can be distinguished. This technique 
is important in obtaining increased colony identification accuracy. 
Virulence attributes 
P. midtocida pathogenicity is dependent on many factors, including 
the presence of bacterial virulence properties. P. muUocida virulence 
attributes are listed in Table 5. 
Capsule The P. rrmltocidxi capsule is inconsistently found, being 
more closely associated with pathogenic rather than nonpathogenic 
strains (84). The indirect hemagglutination test, forming the basis for 
capsular typing, recognizes specific capsule associated antigens. There is 
a relationship between colony morphology and the presence of these 
specific antigens. Capsular groups A and D colonies display a pearl-like 
iridescence in oblique transmitted light (141). 
A capsule forms the outermost surface of P. multocida and, before 
specific antibody development, inhibits normal serum bacteriocidal and 
opsonic activity (84). Mucoid colonies, due to hyaluronic acid in the 
capsule, have been found in all capsuleir group A and a few capsular group 
D strains. A large hyaluronic acid capsule associated with the capsular 
type A strains interferes with alveolar macrophage phagocytosis (136). 
Possessing a greater afRnity for adherence to lung cells (169) and 
cultured with frequency from pneumonic lungs (79, 136), capsuleir type A 
is considerably more important in causing pneumonic lesions than 
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Table 5. Virulence attributes of P. multocida. (119) 
• capsular polysaccarides 
• surface structures such as outer membrane 
• lipopolysaccarides 
• neuraminidase 
• multocidin 
• adhesion structures 
• toxin 
capsular type D (79). Capsular type D is generally considered the type 
most often associated with clinical PAR (77, 156) but toxin production 
has been described in capsular types A and D isolated from pig lung and 
nasal passages during clinical outbreaks (150, 169). 
Outer membrane proteins Outer membrane proteins induce the 
synthesis of protective serum antibodies and are assumed to be important 
determinants for bacterial survival. Their exact biological functions, 
however, are not known (119). 
Lipopolusaccharide endotoxin Lipopolysaccharide endotoxin 
contributes to the pathogenic potential of gram-negative bacteria such as 
P. multocida (53). Its activation of the host defense systems, ultimately 
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resulting in clinical signs and tissue damage, contributes to the 
pathogenicity of disease (53). The lipopolysaccharide electrophoretic 
pattern is conserved between isolates (101) and further study into their 
role in colonization or PAR development has yet to be done. 
Exposure to sub-MIC levels of antibiotics has been shown to alter 
the lipopolysaccharide profile of some toxigenic stains while not affecting 
the expression of structural proteins or toxin. This exposure also 
diminished the virulence and adherence to porcine tracheal rings of 
these strains (97). 
Other virulence factors Other virulence factors awaiting 
additional investigation include multocidin, an iron containing compound 
isolated from some strains (80), neuraminidase (151) and elastase (176). 
Pasteurella colonization may be mediated by cleavage of epithelial 
cell siuface fibronectin by elastase, exposing fibronectin receptors (22). 
A capsular type A P. mnltocida isolated from a pneumonic swine lung 
colonized the tonsils of a human and produced clinical illness. Upon 
investigation, the site of the adherence was thought to be fibronectin 
receptors in the human tonsil (176). Although not yet investigated, there 
is the possibility of such a P. multocida receptor in swine. 
Colonization Colonizing ability and toxin production cire 
considered the most important P. multocida virulence factors (98). As 
early as 1982, Rutter and Rojos described the differences in isolate 
pathogenicity to be associated with the ability to colonize the nasal cavity 
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or produce toxin (149). 
Fimbriae and pill Toxigenic P. multocida associated with 
clinical PAR possesses fimbriae (73, 137, 162). Fimbriae, functioning as 
adhesins, play a role in the colonization and infection of the 
nasopharyngeal mucosa (73). If present on P. multocida infecting 
tracheal epithelial cells and the deeper lung tissue, fimbriae enhance 
neutrophil and macrophage phagocytosis (137). 
The existence of pili is not without some question. iDali et al. (81) 
and Grund et al. (72) used transmission electron microscopy to look for 
pill on toxigenic P. multocida, Grund finding them on only two of 79 
isolates. iDali found no evidence of pili or flagella. Pijoan and Trigo found 
different tissue preparation techniques affected the ability to show 
colonization. They discovered those prepared for light microscopy were 
consistently P. multocida negative, but their preparations for scanning 
electron microscopy showed both turbinate and tonsillar colonization. 
Because of this, they contend discrepancies in the reported presence of 
pili are artifactual and due to different fixation and processing 
techniques, causing delicate pili destruction before examination (137). 
Pili are not an absolute prerequisite for P. multocida upper 
respiratory colony formation. Nonfimbriated toxigenic capsular type A 
cells, as well as fimbriated toxigenic capsular type D cells, can adhere to 
newborn pig turbinate explants (137). 
Sites of infection Although attention has been focused on nasal 
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turbinate infection, alternate infection sites can serve as a source of 
lesion producing toxin (3, 137). The tonsil may play a significant role in 
PAR pathogenesis, serving as a readily available site for colonization and 
as a location for absorbance of pathologic toxin concentrations (3, 5). 
Ackermann et al. found histological lesions from infection in the tonsil 
increased in severity over time without increase in colony forming units. 
Intranasal inoculation could result in ongoing tonsillar infection. Using 
light and electron microscopy, he found P. midtocida free within tonsillar 
crypts and within macrophage and neutrophil phagosomes (3). 
Some controversy regarding colonization in the nasal passage may 
result from experimental procedure. Chung et al., after incubating swine 
turbinate fragments with bacterial suspensions, concluded P. nujltocida 
capsular type A or D was incapable of adhering to ciliated epithelial cells 
(34). It has an affinity to respiratory tract mucus (98) so failure to show 
adherence to turbinate fragments may be due to the processing 
technique, washing from the tissue in vivo produced mucus that acts as a 
receptor site (137). 
Tissue predilection is based on structural characteristics of the 
infecting strain. Jacques et al. foimd capsular type A could adhere in 
greater numbers to porcine tracheal epithelial cells than capsular type D 
(86). Other studies show an increased likelihood of isolating type A cells 
from deeper lung tissues (79, 136). Pijoan and Trigo explain site affinity 
by showing capsular type D is more likely to be fimbriated, allowing 
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adherence to the ciliated nasal turbinate but attracting alveolar immune 
cells. They show a consistently thick hyaluronic acid capstile, without 
fimbriae, in capsular type A. Although being a disadvantage in the nasal 
passages, the thick capsule enhances colonizing capabilities in the lower 
lung by aiding in immune system avoidance (137). 
Relationship with concurrent infections 
Bordetella bronchisevtica B. bronchiseptica is a common 
inhabitant and pathogen of the pig respiratory tract, causing transient 
turbinate hypoplasia but no snout changes in young pigs (27). Many 
clinical and experimental studies have shown enhancement of infection 
and PAR development when B. bronchiseptica is present (76, 118, 125, 
126, 149, 156), but toxigenic P. multocida distribution is more closely 
associated with PAR prevalence than is B. bronchiseptica (27, 156). 
When Soderlund, Norqvist and Thafvelin sampled PAR sind PAR free 
herds, they found no difference in B. bronchiseptica isolation frequency 
between herd types. The frequency of toxigenic P. multocida isolation, 
however, was higher in those herds affected by PAR (156). 
B. bronchiseptica appears to be able to colonize the upper 
respiratory tract without predisposing factors easier than P. multocida 
(48). After experimental inoculation, three times more B. bronchiseptica 
than P. multocida was foimd to adhere to swine nasal epithelial cells 
(118). B. bronchiseptica adherence and infection is probably dependent 
on the amount of B. bronchiseptica specific secreted IgA antibodies 
36 
present in the upper respiratory tract (48). 
The level of B. bronchiseptica infection then influences initial 
colonization efforts of P. multocida. It produces different low molecular 
weight, heat stable substances that alter the nasal cavity conditions to 
favor P. multocida colonization (45, 112). These substances most likely 
Include hemolysin, adenylate cyrclase, an adhesin and a tracheal cytotoxin 
(26, 27). Infection and tracheal cytotoxin causes ciliostasis, cilia 
depletion, lymphocyte and neutrophil submucosal infiltration, and mucus 
accumulation on the tracheal and nasal epitheliimi (45, 118, 140). Mucus 
accumulation and ciliostasis are thought to be principal factors allowing P. 
multocida colonization. 
Viral infections Intriguing is the possible relationship between 
viral respiratory infections and P. multocida colonization. Briggs and 
Frank found increased elastase activity in nasal secretions of calves 
exposed to Infectious Bovine Rhinotracheitis, a herpes virus. 
Quantitatively assaying for nasal secretion elastase and Pasteurella 
hemolytica concentration, they showed increased elastase activity 
preceding colonization and decreased activity before the concentration 
declined (22). They hj^othesized viral infection contributes to 
enhanced bacterial colonization by reducing ciliary clearance, altering 
bactericd nutritional status, altering immune factors and/or exposing or 
altering epithelial surface cell receptors. Elastase has been implicated as 
the cause of fibronectin receptor exposure in one case of hviman tonsillar 
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colonization (176). Herpes viruses endemic in some swine populations, 
such as pseudorabies virus or cytomegalovirus, have yet to be studied 
regarding this type of association with colonization. 
Piracu of adhestns While affinity differences between capsular 
type A and capsular type D have not been found, P. multocida has shown 
an afiSnity for respiratory tract mucus (98). A phenomenon termed 
"piracy of adhesins" may explain the mucus attraction. Filamentous 
hemagglutinin and pertussis toxin, mediating respiratory cilia adherence, 
is secreted by human B. pertussis . These secreted adhesins will edso 
bind and mediate respiratory attachment of Streptococcus pneumoniae. 
Hemophilus influenza and Staphylococcus aureus. This may also occur in 
pigs, involving the adhesins secreted by B. bronchispetica and explaining 
P. multocida adherence to porcine mucus (98). 
^peiimental Infection and Recovery 
Experimental model 
Experimental models developed for PAR study are based on the 
relationship between nasal epithelial irritation or B. bronchiseptica 
infection and P. multocida colonization. Intranasal inoculation after 
instillation of dilute acetic acid, is one method used to initiate 
colonization (49, 128, 165). Acetic acid produces subtle biochemicsil 
changes without overt nasal epithelial damage. These changes are 
temporary compared to those caused by B. bronchiseptica (27). 
Ackermaim et cd. developed an experimental model based on the B. 
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bronchiseptica - P. multocida relationship. Intranasal exposure to a 
sterile toxigenic B. bronchiseptica sonicate, followed by intranasal 
instillation of toxigenic P. multocida, produced typical PAR turbinate 
atrophy (6). 
Whether noninfectious environmental conditions can cause changes 
in the nasal cavity that enhance colonization remain to be investigated. 
Concentrations of ammonia, dust and other pollutants in an enclosed 
facility's air cheinge with seasons and ventilation rates. If irritants are 
present in sufficient concentrations, acetic acid-like changes to the nasal 
epithelium, predisposing to infection, may occur. This could be one 
factor explaining Increased PAR prevalence in pigs grown during the 
winter months (153, 154, 161). 
Recovery of the organism 
Recovery of experimentally or naturally infecting P. multocida is 
inconsistent. Commonly, in an exposed pig, the organism is recoverable 
at intermittent times during a study period. Voets et al. recovered an 
inoculated P. multocida from 79% of directly challenged pigs (170). In 
another study, at 2, 4 £ind 6 weeks post Inoculation 40, 40 and 65 
percent, respectively, of inoculated pigs were culture positive (170). 
Hoffman reported a similar situation after experimental inoculation into 
pigs naturally infected with B. bronchiseptica. Pigs were P. multocida 
culture positive within the first week post challenge and periodically 
during the study. Only one pig remained culture positive throughout the 
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six week testing period (78). Similar intermittent recovery success from 
pigs naturally infected has been reported (77. 110). 
PasteureUa muUocida Toxin 
Introduction 
The toxin produced by P. midtocida has been of interest since 
1975, when the relationship between the toxin and PAR was first 
described (83). Support of this relationship is found in many 
investigations (59. 62. 83, 126. 144). 
Adhesion was best achieved by toxigenic strains, without regard to 
fimbriae presence, hemagglutinin or capsular antigenic type, according to 
Pijoan and Trigo. (137). Chanter (26) and Chanter and Rutter (29) 
propose P. midtocida toxin (PMT) is the main colonization factor 
produced by the bacteria, while Vena et al. found no correlation between 
adherence and PMT (169). 
Many studies agree PMT is produced by either capsular type A or 
D (79, 136, 141, 169). PMT produced from either capsular type is 
serologically (60, 62) and biologically (50, 150) identical, 
A similar toxin may also be produced during infection of species 
other than swine. A bovine isolate was found to produce a toxin with 
biologiced properties similar to PMT. This toxin also was similar to swine 
PMT on Western blot and in polyclonal sind monoclonal antibody reaction 
(90). 
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Characteristics 
PMT is a protein with a molecular weight of 143,000 Daltons on 
SDS-PAGE (1, 59) and 146,306 Daltons by sequence analysis (24). 
Trypsin treatment (cleaving peptide bonds) and soditmi dodecyl sulfate 
or dithiothreitol treatment (breaking disulfide bridges holding 
polypeptide chains and other covalent bonds) yields three fragments (26, 
94). The three fragments are not individually biologically active (94) but 
can reassociate into a fuUy active protein (26). Smith, et al., suggest the 
toxin is internalized by the cell, having an intracellular enzymatic action 
on an unidentified target molecule (171). 
Genetic basis A toxigenic capsular type D P. midtocida 
chromosomal DNA library in E. coli has been developed by Petersen and 
Foged (131) and Lax and Chanter (96). Two clones were identified by 
monoclonal antibody as producing PMT. Genetic mapping of the cloned 
regions identified the gene responsible for PMT production, and it was 
named toxA (131). Subsequently, a DNA probe including the toxA gene 
differentiated toxigenic from nontoxigenic strains of both capsular types 
A and D (60). 
Petersen et al. produced multiple deletions in the toxA gene by 
restriction enzyme digestion. Four purified toxin derivatives, lacking 
different and widely separated regions in amino acid sequence, lacked 
toxic activity. One derivative produced efficient protection against 
challenge in mice and was the basis for a recombinant PAR vaccine (132). 
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Production PMT is first detected after 16 hours of growth 
following inoculation of 10^ CFU/ml in broth culture, when the viable cell 
count reaches 10® CFU/ml (147). This corresponds to the late 
logarithmic to stationary growth phases (27, 147). PMT has not been 
detected in the supernatant of log growth phase cultures but is present in 
ceU lysates of this phase (81). 
PMT does not fit the classical definition of an exotoxin, as it is 
released only upon cell death. Scanning electron microscopy of specially 
stained cells showed PMT in the cell cytoplasm. It was not found on the 
surface or in the extracellular space of intact undamaged cells (81). 
Biological effects PMT biological effects have been well studied, 
especially as they relate to the pathogenesis of PAR. Many species other 
than swine can be affected. In rabbits, pneumonia has been induced 
following iatrogenic administration (33) and a clinical condition similar 
to PAR has been reported to result firom natural toxigenic strain infection 
(42). Turbinate atrophy (59) and death (56, 59) has occurred in rats and 
mice given PMT. 
The sensitivity of BALB/c mice to cell firee P. multocida sonicates 
has been reported to be up to six times greater than that of other mouse 
strains (144). Differences in sensitivity, sind differences in PMT 
preparation purity, may explain reports of a 50% lethal dose (LDgo) in 
mice ranging firom 0.5 to 15 )ig/kg (56). 
Systemic and local ejfects PMT has multiple systemic effects 
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when administered to the pig. These effects may be fatal (32, 115), with 
an LD50 ranging from 50 ng/kg to 800 ng/kg depending on the weight of 
the pig, with lighter weights being most sensitive (56). PMT causes a 
general suppression of a pig's well-being, reducing the pig's activity, food 
intake and production of heat (167). When given by parenteral injection, 
PMT causes hepatic necrosis, enterocyte degeneration, kidney necrosis, 
alveolar wall edema, capillary necrosis at cartilage and bone junctions 
(148, 172), sinusoidal neutrophil infiltration and Kupffer cell 
hypertrophy (109). The toxin has no effect on alveolar macrophage 
activity. This supports the contention that toxigenic strains, primcirily of 
capsular type D, are nonpathogenic in enzootic pneumonia (135). 
The common and consistent lesion in affected tissues is vascular 
endothelial damage (32, 106). Devastating systemic effects, such as liver 
and kidney disfunctions, caused by PMT amounts produced by natural 
infection, suggests nasal turbinate lesions alone do not inhibit growth or 
affect weight gain (115). This may, instead, result from a genereil toxic 
influence (27, 61, 100, 165). 
PMT given by intramuscular (105, 106, 109, 148), intraperitoneal 
(31, 148) or intravenous (148, 172) routes causes nasal turbinate atrophy 
consistent with PAR lesions developing from natural infection. Instilling 
PMT intranasally causes PAR lesions (59), unilateral intreinasal exposure 
causing bilateral nasal turbinate atrophy (43). 
PAR turbinate atrophy is related to bone resorption not 
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compensated for by new bone formation (50, 107). It is generally 
accepted that PMT increases osteoclast number and activity within the 
turbinate matrix, while decreasing osteoblast number and activity (43, 
50. 59, 106, 109), without histological evidence of inflammation (59). 
The increase in osteoclastic activity may be mediated by PNTT stimulation 
of IL-6 release from fibroblasts (143). Work by Ackermann, et al., 
however questions the effect of osteoclasts by showing that even though 
there is rapid bone resorption in the concha, acid phosphatase 
expression and nimiber of osteoclasts in the concha decrease after 
subcutaneous PMT administration (2). 
PMT acts as a chronic stimulus on the whole skeleton, but its 
pathologic influence is seen in the highest bone turnover sites (49, 61). 
The turbinates are the fastest growing bone structure in the very young 
pig (49). Their bony turnover is so intensive the ventral nasal conchal 
scrolls are completely renewed within the first two weeks of life (108). 
As they continue to grow, the bony structure has been estimated to 
multiply 16 times within the first month of life (160). It is not surprising 
PMT given to young pigs can cause PAR lesions as quickly as four days 
postexposure (105). 
Conflicting reports of PMT effects on other bone formation 
locations have yet to be resolved. After giving PMT by various parenteral 
routes, Rutter and Mackenzie found no histopathologic changes in pig 
humeral epiphysis or metaphysis sections or at costochondral junctions 
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(148). Yoshikawa and Hanada (175) and Ackennann, et al. (4), however, 
found histopathologic changes in the epiphyseal cartilage matrix 
throughout the body during spontaneous and experimentally induced PAR 
(175). 
Role in PAR Pathogenesis 
Development of PAR is a multistep process, each step being a 
prerequisite for the next. Local immunity and the normal indigenous 
flora act synergisticaUy, maintaining a balanced bacterial flora in the 
upper respiratory tract (16). PAR begins when the nasal mucosal 
resistance is weakened by B. bronchiseptica, or other infectious or 
noninfectious factors. Toxigenic P. multocida then colonizes the nasal 
mucosa and toxin is produced. The toxin, either by local infiltration or 
systemic absorption, enhances osteoclastic resorption and impairs 
osteoblastic turbinate osseous core sjnithesis. These changes become 
irreversible within a few days. Nasal epitheliimi and submucosa undergo 
secondary atrophy and turbinates may disappear almost completely 
within 10-14 days (49). 
Detection 
Dermonecrosis Both PMT and B. bronchispetica toxin cause 
dermonecrosis when injected intradermally in the guinea pig (30, 51, 
59). The two toxins Eire similsir in some biological properties (56) but do 
not have mutual immunologic sintigenicity (30). Similar dermonecrotic 
lesions resulting from intradermal injection of cell free toxigenic 
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Clostridium peifringens preparations support the nonspecific nature of 
PMT induced skin lesions (51). 
PMT caused dermonecrosis allows dififerentiation between 
toxigenic and nontoxigenic P. multocida. Guinea pig intradermal 
injection of either sterile cell free filtrates or cultures have been widely 
used for PMT assay (41). The dermonecrotic test, however, is time 
consuming, expensive and may be considered unnecessarily cruel. 
Mouse inoculation Mouse inoculation can be used to detect PMT. 
Intraperitoneal injection of toxigenic or nontoxigenic strains is lethal in 
mice. Toxigenicity is determined by death following intraperitoneal 
injection of sterile cell free filtrates. This diagnostic test is now used 
infrequently, due to animal welfare concerns and possible false positive 
results (41, 56). 
Cvtopathic effect PMT produces a cytopathic effect on Vero 
(African green monkey kidney) cell (56) and embryonic bovine lung cell 
monolayers (146). The embryonic bovine lung (EBL) test is the preferred 
cytopathic assay. It is more sensitive and reliable than Vero cell assay 
(56) sind is 10^ to 10"^ times more sensitive than is lethal assay in BALB/c 
mice (147). Detection is reported at 30 to 179 pg levels (54, 56, 59, 
117). An agar overlay technique, using EBL cells, can also be used as an 
in vitro PMT assay (30, 46). 
Monoclonal antibody detection An en2yme linked 
immunosorbant assay (ELISA) to detect PMT has been developed (58). 
46 
Coating specific anti-PMT monoclonal eintibodies onto microtiter wells 
allows detection of toxigenic strains from mixed swtae nasal or 
oropharyngeal cultures (19, 170). 
The sensitivity and specificity of an ELISA using bacterial antigens 
depend on the specificity and quality of the antigen preparations (122). 
Appropriate capsular, somatic or pilar P. multocida antigens that give 
satisfactory ELISA specificity have not been identified. 
PMT is exclusively produced by toxigenic P. multocida and can be 
used as evidence of its presence, even when the colonies are not grossly 
recognized in culture. Through sepsirate studies involving 8000 nasal 
swabs from 215 Danish SPF herds (57), 615 field isolates, 47 P. 
multocida strains (including 13 confirmed toxigenic by dermonecrotic 
and cytopathic effects (169)) and seven reference strains (58), the ELISA 
specificity has been established as very near 100%. It has been approved 
for use in the Denmark PAR eradication program, establishing toxigenic 
strain presence in primary nasal cultures (56). 
The ELISA sensitivity compares favorably with the EBL test. The 
lower detection limit of both tests is 25-50 pg PMT (54). Subcultures, 
producing only 0.1% of the PMT usually produced by toxigenic cultures in 
vitro, can be detected by this assay (56, 90). 
The advantages of the PMT ELISA are many. It is as sensitive and 
specific as the EBL assay and is more reproducible. Single colonies from 
mixed cultures can be detected even when the sample is from heavily 
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contaminated material. Technicians or bacteriologists expert in P. 
multocida identification are not needed (56). The test is independent of 
lab animal use, addressing animsd welfare concerns. It is simple and 
rapid, with one technician able to perform the assay on large numbers of 
samples daily (169). 
Anti-PMT antibody ELISAs measure titer in senmi and body 
secretions, providing evidence of PMT exposure (55). Kimman et al. 
used an indirect double antibody sandwich ELISA for class specific 
anti-pseudorabies virus antibody detection in serum and respiratory 
secretions (92). Measurement of class specific anti-PMT antibody in 
serum and nasal secretions may be possible, giving an indication of PMT 
exposure. Although specific, the test cannot differentiate between 
seroconversion caused by infection or by toxoid immunization. 
In addition to ELISA, an antibody based colony lift test has been 
developed by Magyar and Rimler (102). This test relies on Eintibody 
recognition of PMTT absorbed onto a colony overlay supportive matrix. 
DNA probe ToxA gene identification raises the possibility a DNA 
probe used as a diagnostic toxigenic P. multocida test, however test 
specificity has been questioned. Although some studies show 100% 
specificity of in vitro toxA probe hybridization to toxigenic strains (56, 
116), areas of toxA gene homology in other bacterial species and some 
nontoxigenic strains have been found, causing false positive results (91). 
48 
Lnmimology of the Respiratoiy Mucosal Sui&ce 
Introduction 
The idea of a local immunity system dates to the 1920s (14). Only 
during the last 20 years hcis the relevance of local immunity been applied 
to local immunization (14). Improved methods studying irmiiunoc3rte 
origin and fimction have advanced the common mucosal immune system 
theoiy. New techniques enable specific immimoglobulin titration in 
secretions and serum. 
Kimman et al. found the mucosal antibody responses in sdl mucosal 
secretions were highly similar after pseudorabies virus infection or 
vaccination (92). McDermott and Bienenstock identified mesenteric 
lymph node immune cells localizing in the gut, cervix, vagina, uterus, 
mammary gland and mesenteric lymph nodes. Lung origin cells were 
also found to localize in recipient limgs (111). These concepts are 
important to swine health, as they impact vaccination and disease 
prevention. 
Mucosal defenses 
Brandtzaeg defines the respiratory mucosal defenses based on 
functional divisions. The mucosal immune system works by immune 
exclusion, regulation and/or elimination (21). 
Immune exclusion Immime exclusion uses nonspecific 
mechanisms, and specific responses such as immunoglobulins, to limit 
bacterial colonization and penetration at mucosal surfaces. Nonspecific 
49 
examples include the mucus layer found on the upper respiratory tract 
ciliated epithelial cells. As mucus layer mechanical and hydrophilic 
properties attract and trap bacteria, ciliary action moves the mucus to the 
oropharynx for removal (16, 21). 
Lysozyme and lactoferrin act within the mucus layer, killing 
bacteria or inhibiting growth. Lysozyme is bacteriocidal and 
bacteriostatic, accelerating lysis from antibody activated complement 
fixation (16, 21). Lactoferrin is a bacteriostatic iron binding protein, 
depriving pathogenic organisms of iron (21). 
Cytotoxic T cells predominate in the respiratory epithelium. 
Possessing major histocompatibility class (MHC) I molecules, they are 
one of the first cells to contact foreign bodies and initiate an immune 
reaction (123). 
Immunoglobulin type alpha. Immunoglobulin type alpha (IgA) 
production and secretion is a specific mucosal immune system response 
to antigen exposure. IgA is not as highly specific as the systemic 
immunoglobulin type gamma (IgG). Wider specificity range is an 
advantage when dealing with organisms prone to antigenic drift (21). 
IgA associated with a bacteria reduces its negative surface charge, 
increases its hydrophilicity, promotes hydrophilic mucus layer 
entrapment sind prevents adherence and colonization (16, 21, 89). 
Mucosal surface IgA is of significant protective value against superficially 
replicating organisms (16). 
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IgA neutralizes certain exotoxins and respiratory viruses (21, 89). 
In vitro viral neutralization properties are weak. IgA might be more 
important in vivo in trapping toxin and viral particles within the mucus 
layer and enabling clearing, rather than preventing viral infection by 
neutralization (92). 
Another IgA protective property is its efifective antigen cross 
linking capabilities, promoting microbial agglutination and blocking 
soluble material and allergen absorption (21, 89). This is especially 
important in preventing immune mediated respiratory tract pathology. 
IgA fixation on bacterial surfaces prevents the potent complement 
activator, IgG, from binding and initiating complement component 
release, which can damage host tissues. IgA reduces hydrophobic 
interactions, decreasing the association of phagocytic sensitive bacteria 
with neutrophils and preventing continued pathogenic interleukin 
release (16). Increasing goblet cell mucus release, limiting bacterial 
multiplication by antibody dependent cytotoxicity and suppressing 
immune cell chemotaxis, are additional IgA properties helping safeguard 
against pathogenic mucosal immune reactions (21). 
Respiratory mucous membrcine IgA is primarily in dimer form. Two 
monomeric IgA molecules are bound together by a 12 kDa glycoprotein 
known as the "J chain" to form the dimer (157). 
An 80 kDa glycoprotein called the secretory component (SC) is 
attached at the J chain-IgA junction. SC. homologous to other proteins in 
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t±ie immiinoglobullii superfamily, is the ectoplasmic domain of the 
polymeric IgA. receptor found on the basal side of mucosal glandulsir 
epithelium. It also functions as a stearic inhibitor of proteolytic enzymes 
found in the respiratory tract mucus layer (157). 
Using immunohistochemistry, Brandtzaeg found human glandular 
epithelial cells contain membrane associated IgA and SC. Free SC was 
found within the cell Golgi apparatus while intracellular SC outside the 
Golgi region was coupled with dimeric IgA (20). 
These and other findings, as detailed by Solari and Kraehenbul 
(157), support the following IgA secretion mechanism: SC is synthesized 
on the rough endoplasmic reticulum of the serous secretory epithelial 
cells. After transport to the Golgi apparatus, where it accumulates and 
undergoes a maturation process, free SC is moved to the basal ceU 
membrane. IgA is produced by immunocytes next to the basal cell 
membrane and released in the dimeric form, associated with a J chain. 
Membrane associated SC acts as an epithelial J chain receptor causing 
specific affinity for dimeric IgA by the basal cell membrane. The SC-IgA 
complex is endocytosed, moving to and fusing with the apical plasma 
membrane. The SC receptor anchoring domain is cleared, releasing into 
the glandular lumen dimeric IgA still bound to the ectoplasmic SC 
receptor domain (157). 
IgA immunocj^es are particularly prevalent around the glandular 
cells located deep in the mucosa (16) with some specific differences 
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between the distribution of IgA and IgG. IgA has been regularly located 
between these cells, whereas IgG has irregularly been identified in these 
same areas (20). Also, large IgG concentrations are foimd in interstitisil 
fluid and at the epithelial basement membrane zones, with virtually no 
uptake by the glandular acinar cells seen as with IgA. 
Immunoglobulin, type gamma Because of its low molecular 
weight, IgG appears to diffuse as a transudate from senmi into bronchial 
secretions (89). This occurs by passive difiiision through the epithelial 
intercellular tight junctions during normal physiologic conditions and, 
most particularly, during inflammation when these tight jimctions 
become more permeable (16, 20, 21, 89). 
IgG has a role in immune exclusion. If antigen neutralization or 
elimination is not successful, increasing mucosal permeability facilitates 
foreign material influx between cells. Breakdown of mucosal integrity 
may continue by complement mediated immunopathologic mechanisms 
(21). As this process occurs there is an increase in serum IgG exudation 
through capillary fenestrations, between mucosal cells £ind into the 
respiratory lumen, preventing further antigen invasion. (21) 
The mucus layer carries both IgA and IgG. The IgG source is from 
either transudation, exudation in the presence of inflammation, or local 
synthesis by submucosal immunocytes (89). Mucosal IgA is either 
monomeric, from serum, or dimeric and actively tremsported across the 
respiratory epithelium. Due to the lack of differentiating features, it is 
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impossible to accurately determine exact amounts of immunoglobulins 
derived from these sources (89). 
Immune reaulatioTi Immune regulation is a process resulting 
from antigen presenting cells (APC) emd lymphocyte T and B cell 
interactions. Self and non-self antigens are recognized and particular 
antibody classes (A, D, G or E) are produced and released (21). 
T helper cells Upper respiratory tract APCs are responsible 
for holding or processing antigens in a maimer needed for T helper (T^) 
cell interaction. APCs include macrophages, dendritic cells (Langerhans 
cells) and certain epithelial cells (an example of which is present in 
human tonsillar tissue) (21). They present foreign antigens and HLA-like 
(Human Leukocyte Antigens - a key to immune system "self' recognition) 
native ceU determinants to Tjiicells, which in turn help stimulate B cell 
responses to the foreign antigens (21). 
Til cells with CD4'*" phenotype are the predominant T lymphocytes 
in the lamina propria (124). These cells recognize foreign antigen 
through the MHC class II molecule (123). Mucosal IgA induction is 
dependent on cognate help provided by these 004"^ T cells (123, 139). 
The CD4^ cells also release lymphokines coordinating the immime 
function, altering the normal respiratory physiology (123) and stimulating 
T suppressor cells, to inhibit other than the IgA producing B cell isotype 
(21). 
B cells destined to produce secretory IgA must be continually 
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resuppUed to the respiratory submucosa, maintainiiig the secretory IgA 
supply necessaiy for extended local immune protection. The nasEil 
mucosa has the cells necessaiy for antibody response, but it is not known 
whether the secretion inmiune response is the result of local nasal 
mucosal or oropharynx tymphoepithelial tissue production (45). 
McDermott and Bienenstock (111) and Berstein (16) showed the ability 
of immature B cells, with a potentlEil for J chain production, to become 
stimulated in mediastinal lymph nodes, tonsillar and adenoid tissues and 
then migrate to glandular sites where they are subjected to terminal 
differentiation. The predominant immunoglobulin content of these cells 
is IgA. Brandtzaeg (21) also contends humerally circulating J chain 
positive B cell blasts are continuously seeded into the nasal stroma. 
Signals mediated by locally activated T cells, antigens, mitogens, or local 
hormones then induce B cell differentiation in the tissue. Most of these 
B cells end as IgA dimer producing immunocjrtes, with a few J chain 
positive IgG, IgD and IgM producing immunocytes also developing. 
Interlevkin Ramsey et al. think T^ cell produced interleukin 6 
(IL-6) is one of the primary development signals for in vivo mucosal 
antibody response. By identifying a mouse genetic line incapable of 
producing IL-6, they found the capacity of the mutant mice to mount 
specific intestinal IgA antibody containing cell responses to be grossly 
deficient. Mutant IL-6' mice had substantially fewer IgA plasma cells in 
their intestines, mesenteric lymph nodes and lungs compared to IL-6'^ 
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mice. Finally, the IgA. response in the mutant mice was completely 
restored after intrangisal infection with recombinant vaccinia virus, 
engineered to express IL-6 (139). 
Immune elimination Immune elimination is the functional 
property of the mucosal immune system addressing foreign material 
neutralization and elimination after entering the body. IgG phagocytosis 
enhancement and antibody dependent cytotoxicity involving complement 
or killer cells assist this action. 
In contrast to the superficial and glandular associated IgA 
producing B cells, the IgG immunocytes are present in relatively large 
numbers in the deeper lamina propria layer. During inflammatory 
rhinitis the number of these IgG producing cells increases. Associated 
IgG heis a hydrophobic effect on the bacterial surface, promoting 
engulfinent by phagoc5rtic cells. Persistent IgG immune complexes 
increase capillary and epithelial permeability, sdlowing immunoglobulin 
exudation and entry of mucosal surface bystander antigen into the 
submucosa (16). 
Summaru of mucosal defense mechanisms In summary, the 
mucosal immune system functional components, immune exclusion, 
regulation and elimination, must be active and effective to ensure mucosal 
protection against infection. Two "lines of defense" are operable. The 
first includes nonspecific bacteriocidal or bacteriostatic properties of the 
respiratory mucus coat, lysoz3nme, lactoferrin and other factors. More 
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specific response involves local production of J chain IgA next to SC 
bearing epithelium (21). These factors, and the inhibitory action by the 
indigenous bacterial flora, have a synergistic effect in preventing upper 
respiratory tract bacterial adherence and colonization (16). 
The second line comes into play with the initiation of inflammation. 
Serum tremsferred antibodies eind protective factors in the mucossil 
interstitial fluid act to eliminate submucosal and epithelial antigenic 
materials (21). 
Secretory immunoglobulins 
Tupe of immunoalobulins on mucosal surfaces Nsisal secretion 
and serum immunoglobulin content in the newborn and growing pig has 
been investigated by Morgan and Bourne (114). Without addressing 
vaccination history and using nasal lavage to collect secretions, they 
reported class specific antibody ratios. IgG is. quantitatively, the major 
immunoglobulin in the nasal secretions of these pigs, agreeing with 
studies of himian babies, lambs and calves (114). Using IgArIgG ratios to 
follow relative immunoglobulin level, a transient IgA predominance in 
nasal secretions was seen during the first week of life. The most 
probable explanation is passively acquired IgA selectively being 
transported to the respiratory tract. The IgA: IgG ratio decreases to a low 
at five weeks (0.25:1). Predominance of porcine respiratory tract IgG 
during two to ten weeks of age is a reflection of low IgA content, not 
elevated IgG levels. About the fifth week, local IgA synthesis becomes 
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active, increasing the IgAiIgG ratio until by 11 weeks of age the ratio is 
greater than 1:1. The major immunoglobulin in the adult pig upper 
respiratory tract secretions is IgA (113). 
Using an ELISA to assay for antibodies in pig serum and 
bronchoalveolar fluid after infection with ActinobaciRus pleuropneumonia, 
Loftager and Erisksen found mucosal IgA response rises before a systemic 
antibody response (99). During early stages of natural infection, IgA was 
present in bronchoalveolar fluid and saliva, when no serum antibodies 
were detectable. Later in infection, when antibodies were present in 
serum, very low but detectable IgA levels were found in the 
bronchoalveolar fluid and none in saliva (99). Balfour-Ljnm et al. contend 
that, in the human, such an increase in mucosal IgA during the very early 
infection period is from plasma exudation rather than increased IgA 
production (13). 
Kimman et al. measured mucosal and serum response to 
vaccination with pseudorabies virus (92). They found pseudorabies 
specific IgA in samples for variable periods, however, serum IgG response 
persisted. Intranasal vaccination led to low lung, nasal, tear and saliva IgA 
titers, but an IgA anamnestic response was seen following challenge 96 
days post-vaccination. 
Collection of samples Many studies examining antibody content 
in nassd secretions have used nasal lavage to collect samples (13, 48, 92, 
99, 113, 114). Morgan and Bourne investigated the influence collection 
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method has on immunoglobulin levels in the pig nasal and tracheal 
secretions (113). Nasal lavage was done by collection of instilled fluids as 
they ran out of the nasal cavity while the pig was in a head down, dorsally 
recumbent position. Collection was also done by placing a tampon in the 
nasal passage and expressing the collected fluids. Comparison of these 
two methods showed the IgA:IgG ratio in the tampon samples to be 
significantly less than in nasal lavage samples. In spite of the absence of 
blood, epithelial damage caused by tampons resulted in leakage of IgG 
rich interstitisil fluid into the secretion (113). 
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Abstract 
Thirty-six Landrace by Large White cross gilts were randomly 
assigned to one of three consecutive time blocks, 12 gilts per block. 
Within each block, gilts were randomly assigned to one of three beta-
hydroxy beta-methyl butyrate (HMB) treatments (0 gm, 2 gm or 10 gm) 
top-dressed on the feed once daily, beginning 38 days before the 
expected block farrowing date and continuing through 21 days post-
farrowing. They were housed in groups of three in separate isolation 
rooms before farrowing, and farrowed in a common room with 12 
individual farrowing crates. Within each block each gilt was vaccinated 
with a commercially available killed pseudorabies (PRV) vaccine 2ind a 
tetanus toxoid at separate sites. To test the effect of HMB treatment on 
immunoglobulin class specific htmioral and mucosal antibody titers, gilts 
in each HMB treatment group were randomly assigned to be either P. 
muLtocida vaccinated or non-vaccinated. 
Serum samples were collected on days -38 (before beginning HMB 
treatment), -28, -14, and -7 prefarrowing, and on days I, 7, 14, and 21 
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postfarrowing. Collection of nasal samples was successful on days 38 
prefarrowing, and days 1, 7, 14 and 21, postfarrowing. PRV and tetanus 
antibody titers were obtained on the sera using an ELISA test. A 
modification of a commercially available ELISA designed for detection of 
P. multocida toxin was used to find anti-PNTT class specific antibody titer 
in the sera and nasal secretions. 
Sertmi concentrations of HMB were in proportion to the level of 
UMB fed (p<0.01). The anti-tetanus and anti-PRV titers in those pigs fed 
2 grams of HMB per day tended to be higher than that of the other two 
HMB treatment groups. 
Treatment by feeding HMB appeared to have a suppressing effect 
on sera anti-PMT IgA. Sera anti-PMT IgG was not affected by HMB 
treatment. 
Nasal anti-PMT IgA levels were also variable, with no discemable 
differences among the HMB treatment groups. Anti-PMT IgG levels 
varied but tended to be greater in pigs receiving no HMB on day 1, with 
no discemable differences on the following days. 
There was interaction effect between HMB treatments and 
vaccination on the levels of sera IgA, day 21, and nasal IgA, day 14, with 
those gilts not being vaccinated tending to have the higher titers. 
In this study, HMB vaccination with the particular P. multocida 
bacterin-toxoid used did not effect the level of anti-PMT antibodies in the 
nasal secretions or the sera. Oral HMB treatment with 2 grams per day 
tended to increase response to tetanus toxoid and PRV vaccinations. 
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bitroductioii 
Release of Pasteurella midtocida toxin CPMT) follows natural and 
experimental infection with the toxigenic strain of P. multocida in the 
upper respiratory tract of pigs (9). This toxin can cause progressive 
atrophic rhinitis (PAR) in pigs by Eiffecting the bony nasal turbinate 
osteoblasts and osteoclasts. Intrsmiuscular and intraperitoneal injection 
of purified toxin has been shown to cause turbinate atrophy typical of 
PAR, suggesting the toxin can travel hematogenously (5, 16, 17, 25). 
P. midtocida bacterins, alone and in combination with Bordetella 
bronchiseptica, have been used with varying degrees of success to 
prevent PAR (2). Including a toxoid fraction to these bacterins has 
increased the effectiveness of PAR vaccination programs (14, 19, 23). 
PMT is antigenic and causes humoral antitoxin production when 
given intramuscularly to pigs (10). Anti-PMT antitoxin, given to pigs 
intraperitoneally, is protective against turbinate atrophy after 
intrsmiuscular challenge with PNTT eind after experimental infection with 
toxigenic type D P. midtocida (7, 10). This suggests circulating antibody 
may protect piglets against PMT that is produced in body sites such as 
the lungs or tonsils and reaches the nasal turbinates hematogenously. 
While the primary immunoglobulin in antitoxin caused by 
intramuscular toxoid vaccination is immunoglobulin type gairmia (IgG), 
the major immunoglobulin in the upper respiratory tract secretions of 
adult swine is immunoglobulin type alpha (IgA) (18). IgA is actively 
transported to mucosal surfaces and is of significant protective value 
79 
against superficially replicating organisms (3). preventing adherence, 
mediating bacterial agglutination, and neutralizing certain toxins (15). 
IgG can reach nasal secretions by passive diffusion between epithelial 
cells and through exudation during inflammatory processes (3, 4, 15). 
Intranasal instillation of PMT in piglets can cause severe snout 
lesions without causing a serologic response, as measured by serum 
neutralization tests (10). P. multocida bacterin-toxoid vaccination failures 
to prevent turbinate atrophy (6, 24) may be due to insufificient antibody 
levels on the nasal mucosal surface to inhibit colonization or neutralize 
PMT. 
Beta-hydroxy, beta-methyl butyrate (HMB) is a naturally occurring 
product of leucine metabolism in sheep hepatocytes. Oral HMB 
supplementation in the piglet has been shown to stimulate the immune 
system by enhancing opsonization, stimulating B-lympho^rte 
blastogenesis and increasing macrophage activity (21). 
The objectives of this study were to leam if there is a dose 
response effect of HMB on primary or anamnestic antibody levels 
following EM injection with a tetanus toxoid (primary), a killed 
Pseudorabies vaccine (anamnestic) and a P. multocida bacterin-toxoid 
vaccine (smeimnestic). Immunoglobulin class specific anti-PMT titer was 
measured directly in nasal secretions and serum. To measure antibody 
titer on the nasal mucosa, a method of nasal secretion collection giving 
enough undiluted nasal mucosal surface secretions for antibody titration 
was devised. A commercially available anti-PMT ELISA was modified so 
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immunoglobulin class specific titers in collected nasal secretions and 
sera could be measured. 
Bifaterials and Methods 
Thirty-six Landrace by Large White cross gilts were randomly 
assigned to one of three consecutive time blocks, 12 gilts per block. 
Within each block, gilts were randomly assigned to one of 3 HMB 
treatments (0 gm, 2 gm or 10 gm) top-dressed on the feed once daily, 
beginning 38 days before the expected block farrowing date and 
continuing through 21 days post-farrowing. They were housed in groups 
of three, in separate isolation rooms before farrowing. Each gilt was fed 
separately four pounds of complete 18% protein com and soybean based 
antibiotic free feed once dally before farrowing. Following farrowing, the 
same diet was fed ad libitum, ensuring all offered feed was eaten each 
day. They were farrowed in a common room containing 12 individual 
farrowing crates. 
All gilts were injected intramuscularly in the neck with a 
commercially available kUled pseudorabies (PRV) vaccine* and a tetanus 
toxoid" in separate sites. To test the effect of HMB treatment on 
immimoglobulin class specific himaoral and mucosal antibody titers, gUts 
in each HMB treatment group were randomly assigned to be either P. 
multocida vaccinated or imvacclnated. 
aPRV Gold®, Syntrovet Corp., Lenexa, KS 
bTetanus Toxoid*, Colorado Senmi Corp., Fort Collins, CO 
81 
The P. multocida vaccinated gilts were injected according to label 
directions with a commercially available progressive atrophic rhinitis 
vaccine containing bacterins of Bordetella bronchiseptica and type D 
Pastewella multocida along with a P. multocida toxoid." The Tetanus 
toxoid and PRV vaccines were also given according to label directions. 
Each vaccine was given by individual injection into separate intramuscular 
sites using an 18 gauge, ly inch long needle. Vaccination occurred on 
days -28 and -14, before the projected farrowing date for each block. 
Sterile 13 nmi plastic test tubes'*, sealed with rubber 100 ml. size 
bottle stoppers were used to collect nasal samples. A portable vacuum 
pump was connected to the test tube by rubber tubing attached to a 16 
gauge, 1 inch long needle inserted through the rubber stopper. The 
intravenous end of an 18 gauge Vaccutainer' needle was also inserted 
through the rubber stopper. A six inch length of 20 gauge silastic tubing 
was pushed over the exposed end of the Vaccutainer needle. The free 
end of the tubing was plugged with hematocrit clay and three holes were 
cut in the side of the tubing just proximal to the clay plug. As vacuum was 
applied through the rubber tubing to the test tube, nassil secretions were 
drawn into the test tube and collected in its bottom. 
CAR Vac®, NOBL Laboratories, Orange City, la. 
d 12 X 75 mm Falcon® tube, Becton Dickinson Labware, Lincoln Park, 
New Jersey 
eVaccutciiner® needle, Iowa Vet Supply, Des Moines, Iowa 
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Gilts were restrained by putting a soft cotton rope in the mouth and 
around the snout, tying the rope to either a wall ring or farrowing crate. 
Before collection the head was secured in an upright position and the 
external nares were wiped with a gauze sponge. Nasal secretions were 
collected by vacuimi from each nostril. If, at any time during the 
collection, any blood was visible in the tube or sample, the sample was 
discarded and collection was attempted the following day. Blood was 
collected from the cranial vena cava immediately following successful 
nasal sample collection. 
Serum samples were collected on days -38 (before beginning HMB 
treatment), -28, -14, and -7 prefarrowing, and on days 1, 7, 14, and 21 
postfarrowing. Collection of nasal samples was attempted on days 38 
prefarrowing, and days 1, 7, 14 and 21, postfarrowing. If during 
collections a gilt resisted forcefully enough to endanger her well-being, 
the collection was stopped and attempted the next day. 
Collected nasal sample volumes ranged from one to four milliliters. 
The samples were treinsferred to microcentrifuge tubes said EDTA, 100 
mM, was added to the volimie of nasal sample to reach a final 
concentration of 1 mM EDTA per sample. Sputolysin' was added to the 
sample so the final volume ratio of Sputolysin to sample was 1:200. The 
microcentrifuge tube was mixed on a Vortex mixer and allowed to stand, 
at room temperature, for 30 minutes. Following centrifugation at 1000 
^Sputolysin Reagent*, Calbiochem-Novabiochem Corp., La Jolla, CA 
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RPM for 3 minutes the samples were frozen at -70° C. imtil anafysis. 
Serum was separated from the blood and transferred to labelled 
Falcon tubes. All samples were stored at -70° C. until analysis. 
Concentrations of HMB were measured in the gilt sera according to 
the protocol of Nissen et al. (20) 
Clsiss specific antibody titration was done by a modification of the 
procedure used by Foged et al. (8) ELISA plates, with wells coated with 
monoclonal anti-PMT antibody, were supplied by DAKO Corporation, 
Carpenteria, California®. Serial dilutions of P^^^, harvested from cultures 
of toxigenic P. multocida , according to Ackermstn et al. (1), were assayed 
for activity. One hundred microliters of PMT, diluted 1:250, were 
incubated for 30 minutes, with shaking, in each ELISA well. Nonspecific 
antibody binding was blocked by shaking 100 jil of 1% mouse serum' In 
the wells for 30 minutes. Fifty microliters of appropriate sample serial 
dilutions, beginning at 1:2, were added to the wells and incubated, with 
shaking, for 1 hour. One hundred microliters of 1:1000 smti-IgA or anti-
IgG class specific antibody conjugated with horse radish peroxidase^ were 
added to each well for 1 hour, with shaking. Between these steps, wells 
gDAKO PMT ELISA Kit®, DAKO Corporation, Carpenteria, California 
^National Animed Disease Lab, Ames, Iowa 
'Stellar Bio Systems, Inc., Columbia, MD 
iBethyl Laboratories, Bethyl, TX 
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were washed four times with 200 |il phosphate buffered saline solution 
with 0,5% TWEEN. A substrate of 100 OPD solution prepared 
according to kit directions was added and incubated without shaking, in 
the dark, for 15 minutes. AU incubations were at room temperature. 
Color development was stopped by the addition of 100 H2SO4 supplied 
with the ELISA kit and optical density was read by an automatic optical 
density reader at 490 nm. The titer was calculated using extrapolation 
between the log values of the end titer dilutions, according to directions 
supplied with the ELISA kits. 
Nasal swabs were taken on each sampling day and streaked for 
bacterial isolation on both 5% sheep blood agar and P. rnidtocida selective 
agar, prepared according to the procedure of Hof&nan (13). 
Identification of individual colonies of P. midtocida was done using 
standeird biochemical tests. The DAKO PNTT ELISA* test kit verified 
toxigenicity of the cultures. 
Sera was submitted to the Iowa State University College of 
Veterinary Medicine Diagnostic Lab for G1 deleted differential 
pseudorabies titer determination. Anti-tetanus titers were performed 
using an ELISA, according to the procedure of Goff et al. (12) 
Data were anal)^ed by the general linear models procedure of SAS 
using baseline serum titers as covariates for the Pseudorabies and Tetanus 
titers. The immimoglobulin class specific anti-P^^^ antibody titers were 
analyzed by the general linear models procedure of SAS, after subtracting 
the initial baseline titers from all results. 
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Results 
Cultures 
No toxigenic P. rmdtocida was isolated from the gilts during the 
trial. 
Sera HMB 
Sera concentrations of HMB are shown in Figure 1. All day values 
are relative to farrowing (day 0). Sera concentrations of HMB on day -38 
were from samples taken before beginning dietary supplement with HMB 
and were not statistically unique in any of the treatment groups. 
Statistically significant differences among treatment groups were found 
during each of the subsequent sampling dates. Significance was at 
p<0.01 for each of these measurements. 
Figure 1. HMB sera levels in gilts fed var3^g levels of HMB top-dressed 
on the feed. For all points across treatments p<0.01. 
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Anti-tetanus titers 
The sera anti-tetanus titers are detailed in Figure 2. The titer on 
day -38 was the baseline titer calculated by the covariate analysis. 
Figure 2. HMB effect on sera anti-tetanus titers, log base 2, of gilts fed 
varying levels of HMB. 
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Samples taken on day -38 were done so before vaccination and dietary 
supplement with HMB. 
Anti-pseudorabies virus titers 
Figure 3 represents the log base 2 anti-PRV titers. All days are 
compared with farrowing (day 0). The titer on day -38 was the baseline 
titer calculated by the covariate analysis. Samples taken on day -38 were 
done so before vaccination and dietary supplement with HMB. 
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Figure 3. Sera anti-pseudorabies titers (log base 2) of gilts fed varj^g 
levels of HMB once daily.Class specific anti-PMT titers 
1.00 
SEM = 0.5 
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Figures 4 through 11 show the class specific anti-PMT titers by day 
relative to farrowing (day 0) in the sera and nasal secretions as a function 
of vaccination and treatment with HMB. The nasal samples and their 
corresponding sera samples were collected on days -38, 1. 7, 14 and 21. 
All values were corrected by subtracting the respective baseline titer 
foimd on day -38. This allows statistical analysis of the data from a 
starting titer of zero on day -38. 
88 
Figure 4. Vaccination effect on sera anti-PMT IgA. titers in gilts fed 
varying levels of HMB once daily (PMT vaccination on days -
28 and -14). 
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Figure 5. HMB effect on sera anti-PMT IgA titers in gilts fed varying 
levels of HMB once daily (PMT vaccination on days -28 and -
14). 
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Figure 6. Vaccination effect on sera anti-PMT IgG titers in gilts fed 
varying levels of HMB once daily (vaccination on days -28 and 
-14). 
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Figure 7. HMB effect on sera anti-PMT IgG titers in gilts fed varying 
levels of HMB once daily (PMT vaccination on days -28 and 
-14). 
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Figure 8. Vaccination ejBFect on nasal anti-PR/TT IgA titers in gilts fed 
varying levels of HMB once daily (vaccination on days -28 and 
-14). 
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Figure 9. HMB effect on nasal anti-PMT IgA titers in gUts fed varying 
levels of HMB once daily (PMT vaccination on days -28 and 
-14). 
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Figure 10. Vaccination eflfect on nasal anti-PMT IgG titers in gilts fed 
varying levels of HMB once daily (PMT vaccination on days 
-28 and -14). 
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Figure 11. HMB effect on nasal anti-PMT IgG titers in gilts fed varying 
levels of HMB once daily (PMT vaccination on days -28 and 
-14). 
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Discussion 
Today's pork production industry relies less on treatment of 
disease and more on prevention. Because of the economic consequences 
of disease treatment, more emphasis has been placed on disease 
prevention. Part of most pork producer's disease prevention strategy 
uses vaccines. Identifying a technology allowing the use of fewer animal 
hecdth products is important to pork producers because of the potenticd 
for decreasing costs of production. 
Beta-hydroxy, beta-methyl butyrate (HMB) has shown some promise 
to be an immune system stimulator. Heightening immune system status, 
particularly that of the mucosal surfaces, may give the pig protection from 
infectious agents that could affect the pig's growth performance. This 
study attempted to evsduate the usefulness of HMB as an immune system 
enhancer. Hie gilts were given their respective dose of HMB. top-
dressed on their feed once daily, beginning approximately 38 days before 
farrowing. There was some variation in gestation lengths so an individual 
gilt may have received HMB for a longer or shorter time than 38 days. 
One gilt did farrow uneventfully 2 weeks before the date specified by her 
breeding date and she was removed from the study. All other gilts 
farrowed within a few days of the scheduled farrowing dates. 
Table 1 shows the gilts successfully absorbed the fed HMB. There 
is a statistical difference at the p<0.01 in the sera levels of HMB between 
treatments. The drop in HMB level in the 10 gram treatment group at 
farrowing is not enough to change the p<0.01 probability. 
A tetanus toxoid was included in the vaccination protocol as an 
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attempt to use an immimogen that would give a primary immunological 
response. None of the gilts were serologically negative to tetanus toxin at 
the beginning of the study, so a primary response was not able to be 
evaluated. The specificity of the ELISA used in the anti-tetanus antibody 
assay had not been investigated sufficiently to rule out cross reaction with 
antibodies against Clostridial toxins a pig may routinely contact, such as 
from Clostridium perfringens. 
The anti-tetanus titer in those pigs receiving 2 grams of HMB per 
day tended to be consistendy higher than that of the other two groups. 
Vaccination was given on day -28, and by day -14 the 2 gram HMB 
treatment group had a statistically higher titer than either the 0 or 10 
gram treatment groups. No anamnestic response to vaccination was seen 
after the day -14 vaccination. 
A commercial swine herd was the source of the gilts. They had 
been vaccinated against pseudorabies at the time of breeding but were 
negative to anti-wild virus pseudorabies antibodies by the differential 
ELISA used in the Iowa State University College of Veterinary Medicine 
Diagnostic Laboratory at the beginning and throughout the study. 
Except on day -14, PRV antibody titer in the 2 gram HMB 
treatment group consistently tended to have higher titers than either the 
0 or 10 gram groups. On days -28 and -7 the difference between the 2 
and 0 gram groups was statistically significant at the p<0.10 level. The 
high titer of the 0 gram gilts on day -14 is not explainable. The high 
value may be due to statistical variation, as there was no significant 
difference among the levels on this day. HMB did not affect the 
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pseudorabies titers postfarrowing, other than on day 1, in which the gilts 
fed 10 grams HMB were significantly lower than those fed 2 grams. 
HMB effect on class specific antibody production is variable and 
needs to be further studied to understand its effects. The senmi levels of 
anti-PMT IgA appeared to have been suppressed by HMB 
supplementation (Figure 5). There was a significantly higher serum IgA 
level on day 21 in the gilts not fed HMB. Also, the trend in the serum 
appears to be for the non-supplemented pigs to have higher IgA levels 
than those supplemented. Serum anti-PMT IgG levels (Figure 7) were 
variable enough that no pattern emerges except at day 1. when the 2 gm 
HMB group had the highest titer. 
Nasal anti-PMT IgA levels (Figure 9) were also variable, with no 
discemable differences among the HMB treatment groups. Nassd anti-
PMT IgG levels, seen in Figure 11, varied but tended to be greater in pigs 
receiving no HMB on day 1, with no discemable differences on the 
following days. 
Vaccination with the bacterin-toxoid combination didn't greatly 
affect sera or nasal class specific cmtibodles. There was a vaccine effect 
on sera anti-PMT IgA levels on days 1 and 21 (Figure 4) but the results 
are somewhat imexpected in that the titers of the non-vaccinated gilts 
were greater than those vaccinated. The proof of a vaccine is in clinical 
and economic response, but in this measurement vaccination did not 
appear effective. 
The vaccination and HMB interaction was primarily imremarkable. 
There was some interaction with HMB on the levels of sera IgA, at day 
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21, and nasal IgA, at day 14, with unvaccinated gilts tending to have the 
higher titers. HMB supplementation in the non-vaccinates produced a 
higher titer on day 14 than that in the gUts receiving no HMB. 
There is a downward movement in the anti-tetanus, anti-
pseudorabies and sera and nasal anti-PMT titers within the first 2 weeks 
post-farrowing. This is most striking in the anti-pseudorabies titers 
(Figure 3). All gilts had a remarkable decrease in titer on day 1. 
Vaccination protocols are designed to maximize titer at farrowing. This 
drop was unexpected and may be related to movement of antibody Into 
colostrum or parturition stress factors, but this needs clarification. 
The apparent HMB inhibition of sera IgA. response, which was not 
strongly statistically supported, is not well explained by this study. It 
conflicts with the increase in anti-tetanus and anti-pseudorabies caused 
by feeding 2 gm HMB, seen in Figures 2 and 3. Still, several possibilities 
other than statistical variation exist. 
The itnmime response starts with an antigen presenting cell (APC) 
processing the antigen and presenting it, on its surface, to T and B cell 
lymphocytes. The T helper lymphocyte (Th) is thought to then contact 
the presented antigen, release interleukins that stimulate B cell response 
and facilitate the interaction of the B cell with the presented antigen 
(22). HMB, when fed to chickens as 0.1% of their diet, has been shown 
to stimulate macrophage (an APC) activity and B cell response. For 
chickens receiving HMB at 0.05% of their diet, macrophage activity and 
lymphocyte response was depressed below control levels (21). It is 
possible HMB has a depressing activity on antigen presentation or B cell 
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activity when it is fed below a certain threshold level. The work in the 
chicken does not address what effect supplementing a percentage of the 
diet higher than 0.1% may have. 
The pigs in this study were given four pounds of feed daily during 
gestation, then fed ad libitum post-farrowing. Ten grams of HMB 
supplemented once daily would account for approximately 0.1% of the 
daily intake during gestation. Further testing is required to be able to 
state whether or not HMB at 0.1% of the diet in the pig is inhibitory or 
stimulatory. With two grams of HMB (approximately 0.02% of the pre-
farrowing diet) appearing to stimulate the immune response to 
pseudorabies and tetanus toxoid, it is possible a certain intake of HMB 
may be stimulatory to antigen presentation or B cell reaction to specific 
antigens and not to others. 
Another potential effect of HMB involves immune response 
differentiation. Comparing Figures 5 and 7 shows at least an initial 
preference for production of IgG when treated with HMB. Differentiation 
and maturation of the Immune response is influenced by Th cells with a 
CD4* phenotype releasing l5miphokines that help coordinate the immune 
function (22). ^^MB at specific levels in the diet may have an influence on 
the isotj^e of antibody produced during an immune reaction by affecting 
the type or ratio of lymphokines released. The anti-tetanus and anti-
pseudorabies titers measured total antibody titer, wliich may have 
masked a preference to one antibody isotype. 
Many factors are involved in transmission of P. multocida and the 
occurrence of clinical progressive atrophic rhinitis. Vaccination 
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programs have been one practice pork producers have used to help 
prevent the physical and economic effects of the condition. In this study, 
the vaccine used did not appear to greatly effect the level of sinti-PMT 
antibodies in the nasal secretions or the sera. Further study, designed to 
evaluate the protective response of vaccination to exposure, could help 
determine the vaccine's effectiveness. 
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IV. SYSTEMIC AND LOCAL ANTIBODY RESPONSE IN THE PIG 
AS AN INDICATION OP 
TOXIGENIC PASTEVRELLA MULTOCIDA TYPE D TRANSBHSSION 
A paper prepared for the journal Infection and Immunity 
Paul L. Sundberg, Eldon K. Uhlenhopp 
and Lorraine J. HofBnan 
Abstract 
Twenty crossbred barrows and gilts six weeks of age were housed 
in groups of five and randomly assigned according to a 2x2 factorial 
design with treatments being vaccination and experimental intranasal 
exposure with a toxigenic strain of type D Pastewella multocida. The 
vaccinated pigs were injected with a commercially available progressive 
atrophic rhinitis vaccine consisting of Bordetella bronchiseptica and P. 
multocida bacterins with a P. multocida toxin (PMT) toxoid. Vaccination 
preceded experimental exposure by 7 days. 
Nasal secretions and serum samples were collected and assayed for 
class specific anti-PMT antibodies. Nasal secretion samples were 
collected before experimental exposure and 35 days later. Blood was 
collected by anterior vena cava venipuncture on days 0, 7, 21, 35. 98 and 
124. 
Nasal swabs were taken on days 0. 7, 21, 35 £ind 70 and streaked 
for bacterial isolation. Identification of individual colonies of P. multocida 
was performed using standard biochemical tests. A sandwich ELISA 
verified toxigenicity of the cultures. 
The pigs were examined at slaughter for evidence of nasal turbinate 
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damage consistent with progressive atrophic rhinitis and limg 
consolidation. 
Recovery of the organism on each sampling day, from even the 
experimentally exposed pigs, was not consistent. Only 6 of the 10 
experimentally exposed pigs yielded recoverable P. multocida dming the 
trial. Transmission to non-experimentally exposed pigs was 
demonstrated by culture as early as 7 days post experimental exposure 
with infection continuing as late as day 70. 
No vaccinated, non-experimentaUy exposed pigs were culture 
positive on any of the sampling dates suggesting protection from 
transmission by vaccination. Vaccinated, non-experimentally exposed 
pigs were less culturable on day 7 (p<0.1) than were vaccinated and 
experimentally exposed pigs. 
The most nasal turbinate damage tended to be in the pigs that were 
neither vaccinated nor experimentally exposed. The lowest scores 
tended to be in the pigs that, although they were experimentally 
exposed, were also vaccinated. 
Anti-PMT IgG in the sera appears to be a good indicator of 
exposure, supporting the hypothesis that the non-experimentally 
exposed pigs became exposed by transmission within 21 days. Anti-PMT 
serum IgG tended to be highest in vaccinated pigs. Senmi anti-PMT IgA 
does not appear to be as sensitive an indicator of exposure or vaccination. 
Nasal secretion anti-PMT IgA can be used as an indication of 
transmission. Nasal titers for both the experimentally exposed and non-
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exposed groups tended to move together, indicating transmission. 
It appears there are different abilities of all of these measurements 
to detect transmission. Turbinate damage is the least specific indication 
and does not correspond well with other methods. Culture results and 
serological and mucosal assay do support each other. The exposed pigs 
were more likely to be culture positive on day 7 and they had a high anti-
PMT IgG titer by that day. Antibody assay and culture results suggested 
transmission had occurred. Finally, culture and antibody titer implied a 
protective effect from vaccination. 
Introduction 
Mucosal antibody responses after infection or vaccination are highly 
similar. The mucosal immune system in the eyes, upper respiratory 
tracts, and upper alimentary tracts of pigs apparently react, 
immunologically, as a whole (13). 
Morgan and Bourne measured class specific antibodies collected by 
nasal lavage from piglets up to 10 weeks of age (16). They found the 
major change that occurs in the immtmoglobulin content of respiratory 
tract secretions of piglets between 2 and 10 weeks of age is an increase 
in the concentration of IgA due to an increase in mucosal IgA synthesis. 
While the major immunoglobulin in the upper respfratory tract secretions 
of adult swine is IgA (15), IgG can reach nasal secretions by passive 
diffusion or leakage, particularly in inflamed mucosa (2). 
Progressive atrophic rhinitis (PAR) is caused by the increase in 
osteoclastic activity and decrease in osteoblastic activity in the nasal 
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turbinates after exposure to the toxin of Pasteurella midtocida (PMT), 
independent from an inflammatory process (8). Intramuscular, 
intravenous, intraperitoneal, subcutaneous, (5, 14, 17, 18) and intranasal 
(6, 8) administration of P^^^ have caused turbinate lesions associated 
with PAR. 
It is possible intranasal infection with P. mLdtocida may not cause 
an immimological response to the toxin. PMT repeatedly instilled 
intranasaUy did not cause a serologic response, as measured by the serum 
neutralization test in mice, although severe snout lesions were found (9). 
Pigs naturally infected with large numbers of toxigenic P. muLtocida in 
the nasal cavity did not develop a detectable serological antitoxin antibody 
response when measured by toxin neutralization assays (3). 
Intramuscular administration of PMT, however, has been shown to 
result in a powerful antibody response that may be protective (9). Anti-
PMT antibodies have protected piglets challenged by intramuscular 
injection of PMT (9) or by experimental intranasal infection with 
toxigenic P. mvitocida type D (4). 
Intramuscular injection b5^asses the nasal mucosal barrier and 
experimental intranasal infection causes artificial irritation of the nasal 
mucosa. Either way, these sources of PMT offer the opportunity for 
serum derived IgG to play a role in toxin neutralization on the nasal 
mucosal surface. 
This study measured the class specific anti-PNTT antibody titer in 
the serum and directly in nasal secretions to attempt to detect 
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txansmission of toxigenic P. multocida. Direct collection of nasal 
secretions was used to ensure antibody titers were located on the nasal 
mucosa and could not have been accidentally washed into the collection 
from the oro-pharyngeal cavity, as could happen with some nasal lavage 
techniques. Culture of nasal swabs and development of an anti-PMT 
antibody titer in the nasal secretions or in serum were compared as 
methods to detect transmission. The effect of vaccination on local and 
systemic anti-P^^^ antibody levels, P. multocida colonization, and 
development of nasal turbinate degeneration were also studied. 
Materials and Methods 
Twenty crossbred barrows and gilts six weeks of age were randomly 
assigned to one of four isolation rooms, five pigs in each room. They 
were fed ad libitum an 18% protein, antibiotic free diet. 
Within each room, pigs were randomly assigned according to a 2x2 
factorial design with treatments being vaccination and experimental 
intranasal exposure". Those pigs to be vaccinated were injected 
intramuscularly with a commercially available progressive atrophic 
rhinitis vaccine consisting of Bordetella bronchiseptica and Pasteurella 
multocida bacterins with a PMT toxoid.'' Non-vaccinated pigs were 
injected intramuscularly with sterile saline. Vaccination preceded 
experimental exposure by 7 days. 
aToxlgenic P. multocida strain number P4148, National Animal Disease 
Laboratory, Ames, Iowa 
bAR Vac, NOBL Laboratories. Orange City, LA 
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Experimental exposure was by the method of Ackerman et al. (1) 
Pigs in the non-experimentally exposed group were instilled intranasally 
with sterile media identical to that used to grow the toxigenic P. 
multocida inoculimi. 
Sterile 13 mm plastic test tubes^ sealed with rubber 100 ml. size 
bottle stoppers were used to collect nasal secretion samples. A portable 
vacuum pump was connected to the test tube by rubber tubing attached to 
a 16 gauge. 1 inch long needle inserted through the rubber stopper. The 
intravenous end of an 18 gauge Vaccutainer'^ needle was also inserted 
through the rubber stopper. A six inch length of 20 gauge silastic tubing 
was pushed over the exposed end of the Vaccutainer needle. The free 
end of the tubing was plugged with hematocrit clay and three holes were 
cut in the side of the tubing just proximal to the clay plug. As vacuum was 
applied through the rubber tubing to the test tube, nasal secretions were 
drawn into the test tube and collected in its bottom. 
Nasal secretion samples were collected before experimental 
exposure and 35 days later. Sample volumes ranged from one to four 
milliliters. The samples were transferred to microcentrifuge tubes and 
EDTA, 100 mM, was added to the volume of nasal sample to reach a finsd 
concentration of 1 mM EDTA per seimple. Sputolysin' was added to the 
c 12 X 75 nmi Falcon® tube, Becton Dickinson Labware, Lincoln Park, 
New Jersey 
dVaccutainer® needle, Iowa Vet Supply, Des Moines, Iowa 
eSputolysin Reagent®, Calbiochem-Novabiochem Corp., La JoUa, CA 
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sample so the final volume ratio of Sputolysin to sample was 1:200. The 
microcentrifuge tube was mixed on a Vortex mixer and allowed to stand, 
at room temperature, for 30 minutes. Following centrifugation at 1000 
RPM for 3 minutes the samples were frozen at -70° C. until anafysis. 
Blood was collected by anterior vena cava venipuncture on days 0, 
7, 21, 35, 98 and 124 and the serum was separated and saved. All 
samples were frozen at -20° C. until assayed. 
Class specific antibody titration was done by a modification of the 
procedure used by Foged et al. (7) ELISA plates, with wells coated with 
monoclonal anti-PMT antibody, were supplied by DAKO Corporation, 
Carpenteria, California^ Serial dilutions of PMT, harvested from cultures 
of toxigenic P. multocida^, according to Ackerman et al. (1), were assayed 
for activity. One hundred microliters of PMT, diluted 1:250, were 
incubated for 30 minutes, with shaking, in each ELISA well. Nonspecific 
antibody binding was blocked by shaking 100 /il of 1% mouse serum** in 
the wells for 30 minutes. Fifty microliters of appropriate sample serial 
dilutions, beginning at 1:2, were added to the wells and incubated, with 
shaking, for 1 hour. One hundred microliters of 1:1000 anti-IgA or anti-
IgG class specific antibody conjugated with horse radish peroxidase' were 
fDAKO PMT ELISA Kit®, DAKO Corporation, Carpenteria, California 
gNational Animal Disease Lab, Ames, Iowa 
hStellar Bio Systems, Inc., Columbia, MD 
iBethyl Laboratories, Bethyl, TX 
107 
added to each well for 1 hour, with shaking. Between these steps, wells 
were washed four times with 200 ^il phosphate buffered saline solution 
with 0.5% IWEEN. A substrate of 100 nl OPD solution prepsired 
according to kit directions was added and incubated without shaking, in 
the dark, for 15 minutes. All incubations were at room temperature. 
Color development was stopped by the addition of 100 |j1 H2SO4 supplied 
with the ELISA kit and opticed density was read by cin automatic optical 
density reader at 490 nm. The titer was calculated using extrapolation 
between the log values of the end titer dilutions, according to directions 
supplied with the ELISA kits. 
Nasal swabs were taken on days 0, 7, 21, 35 and 70 and streaked 
for bacterial isolation on both 5% sheep blood agar and P. mvltocida 
selective agar that was prepared according to the procedure of HofBman 
(12). Identification of individual colonies of P. multocida was performed 
using standard biochemical tests. The DAKO PMT ELISA® test kit 
verified toxigenicity of the cultures. 
The pigs were examined at slaughter for evidence of lung 
consolidation sind nasal turbinate damage consistent with progressive 
atrophic rhinitis. The space between the ventrsil aspect of the turbinate 
scrolls and the ventral floor of the nasal passage was measured in 
millimeters. This measurement was then compared to the values in 
Table 1 to assign a rhinitis score. In this system a space of 3 to 6 mm is 
considered normal, with greater or lesser values indicating PAR 
pathology. 
108 
Table 1. Scale for Scoring Turbinate Atrophy 
Space between tuzbinates and nasal 
passage floor (mm) Score Interpretation 
0 to 2 1 negative 
3 to 6 0 negative 
7 to 9 1 negative 
10 to 12 2 suspect 
13 to 16 3 mild atrophy 
17 to 20 4 moderate atrophy 
21 or more 5 severe atrophy 
Modified from TRAC slaughter check form, Elanco Animal Health. 
Indianapolis, Indiana 
Serum and nasal immunoglobulin data were analyzed using the 
general linear models procedure of SAS with baseline titers as covariates. 
Other data were analyzed using the SAS general linear models procedure. 
Results 
Culture 
Table 2 shows only one of the ten non-experimentally exposed pigs, 
pig mmiber 235 in room 10, cultured positive for toxigenic P. multocida 
at the first sampling date which was 7 days after contact with 
experimentally exposed cohorts. Six of the ten experimentally exposed 
pigs had a positive culture at least once during the sampling period, as 
early as day 7 and as late as day 70. No pigs that were vaccinated and 
non-experimentally exposed were culture positive during the study. 
Nasal cultures were given a value of one if toxigenic P. multocida 
was isolated and zero if it was not. Statistical analysis is shown in Table 3. 
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Table 2. Identification, vaccination and experimental exposure status 
and culture results of pigs experimentally and non-
experimentally exposed to toxigenic P. multocida. 
Days Post Experimental Exposure 
Room ID Vacc Exper Exposure 0 7 14 21 28 35 42 70 
7 231 + — 
7 232 + + - + + + + + + -
7 233 - + - + + + + + -
7 245 + + - + 
7 247 - - - - + + - - + + 
8 230 + 
8 241 - + 
8 242 + + - - + — - - - -
8 244 - + -
8 248 - -
9 237 + + - + 
9 239 - - - - - — - - - -
9 243 + 
9 246 - + -
9 249 - - - - - - - - - -
10 234 - + -
10 235 - - - + + — - + + -
10 236 + + - - + + - - - + 
10 238 + 
10 240 + 
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Table 3. Numerical scoring of culture results from nasal swabbing of 
pigs, by treatment group: 0 = culture negative, 1 = culture 
positive. 
Days Post Experimental Exposure 
Treatment Group 0 7 21 35 70 
not vacc, non-exp exposed 0 0.4 0.0 0.4 0.2 
not vacc, exp exposed 0 0.2 0.2 0.2 0.0 
vacc, non-exp exposed 0 0.0* 0.0 0.0 0.0 
vacc, exp exposed 0 0.6* 0.2 0.2 0.4 
p<0.1; AveSEM = 0.2 
There was a lower recoverability on day 7 from those pigs 
vaccinated and non-experimentally exposed when compared to the 
vaccinated and experimentally exposed pigs. This was the only 
statistically significant difference among any of the treatment groups. 
Rhinitis scores and lung examination 
Table 4 shows the mean rhinitis score for each treatment group. 
The not vaccinated, non-experimentally exposed pigs had a higher mean 
rhinitis score than either the not vaccinated, experimentally exposed or 
the vaccinated, experimentally exposed pigs, with statistical significance 
at the p=0.15 and p=0.13 levels, respectively. 
Table 4. Mean rhinitis scores of pigs by treatment group. 
E^qK>sure 
yes no MEAN 
yes 
VACC 
no 
2.4" 
2.7* 
2.8 
3.8*^ 
2.6 
3.3 
MEAN 2.6 3.3 
''p=0.15, °p=0.13; Ave SEM = 0.5 
I l l  
No gross lung lesions were found in any of the pigs after slaughter. 
anti-PMT antibody in the nasal secretions and serum 
The log base 2 class specific anti-PMT cintibody titers of the sera 
are shown in Figures 1 through 4. Figure 1 shows the anti-PMT IgG level 
as affected by exposure. There was an initial increase in serum anti-PMT 
IgG in both the experimentally and non-experimentally exposed groups. 
The rise in titer in the experimentally exposed pigs occurred by day 7 
post-experimental exposure, then tended to level off through day 128. 
The non-experimentally exposed pigs had a later titer increase (day 21 
after inoculation of the experimentally exposed pigs), leveled off through 
day 70 then began a steady increase through day 126. Figure 2 shows the 
anti-PMT IgG level as affected by vaccination. The vaccinated and non-
vaccinated pigs both increased in titer, roughly parallelling each other 
until day 128. 
Experimental exposure had no statisticsd effect on serum anti-PMT 
IgA but, there was a trend for the serum anti-PNTT IgA in the 
experimentally exposed group to increase, post-exposure, while 
decreasing in the non-experimentally exposed pigs (Figure 3). By day 72, 
the non-experimentally exposed group had increased serum sinti-PMT 
IgA to roughly the same level as the other group. The serum anti-PMT 
IgA levels as a function of vaccination (Figure 4) were approximately the 
same through day 21, post-exposure, then the non-vaccinated group 
tended to have a parallel but higher titer than the vaccinated pigs. 
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Figxire 1. Efifect of exposure to toxigenic P. multocida on sera anti-PMT 
IgG Oog base 2) in pigs. 
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Figure 2. Effect of vaccination with a bacterin/toxoid atrophic rhinitis 
vaccine on sera anti-PMT IgG (log base 2) in pigs. 
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Figure 3. Effect of exposure to toxigenic P. multocida on sera anti-PNTT 
IgA (log base 2) in pigs. 
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Figure 4. Effect of vaccination with a bacterin/toxoid atrophic rhinitis 
vaccine on sera anti-PMT IgA (log base 2) in pigs. 
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Care was taken during nasal sample collection to assure there was 
no blood contamination of the nasal samples. They were considered to be 
contaminated If any visual indication of blood was noted in the samples 
either during or after collection. Nasal samples were collected 
successfully before experimental exposure and 35 days later. 
Thirty five days after experimental exposure no statistically 
significant effect of vaccination or exposure was seen in the nasal class 
specific anti-PMT titers (Figures 5 through 8). In Figure 5 the nasal level 
of anti-PMT IgA is shown to be the highest in the experimentally exposed 
pigs on day 35. Nascd anti-PMT IgG and IgA. tended to be higher in the 
non-vaccinated pigs by day 35 (Figure 6). Figure 7 shows nasal anti-PMT 
IgG was higher in non-vaccinated and experimentally exposed pigs than 
in vaccinated and non-experimentally exposed pigs on day 35 (p=0.08). 
The non-vaccinated, not experimentally exposed £ind the vaccinated, 
experimentally exposed pigs both had very close to identical increases in 
anti-P^rr IgG levels. The nasal anti-PMT IgA levels of the non-vaccinated 
pigs tended to increase by day 35 while the level in the pigs that were 
vaccinated remained steady (Figure 8). This trend appeared to be 
independent firom experimental exposure status. 
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Figure 5. Effect of exposure to toxigenic P. multocida on nasal anti-
PMT IgG and IgA (log base 2) in pigs. 
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Figure 6. Effect of vaccination with a bacterin/toxoid atrophic rhinitis 
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Figure 7. Anti-PMT IgG in nasal secretions by vaccination and 
experimental exposure treatment groups 
CI 
V 
CUD 
a 
0) 
3.00-
2.50-
2.00-
1.50-
1.00-
0.00 
notvacc, 
not exp 
exposed 
notvacc, 
exp 
exposed 
vacc, 
not e  ^
exposed 
vacc. 
• day 0  ^day 35 
Figure 8. Anti-PMT IgA in nasal secretions by vaccination and 
experimental exposure treatment groups. 
2.50-/ 
o 
V 
3 
.o 
V 
1.50-
0.50-
notvacc, 
not exp 
exposed 
notvacc, 
exp 
exposed 
vacc, 
not exp 
exposed 
vacc, 
exp 
exposed 
• day 0  ^day 35 
117 
Discussion 
Vaccination programs designed to prevent the clinical and 
economic effects of PAR are widely used in pork production. For many 
producers the product and labor costs associated with these programs 
are considered a cost of doing business. The wider acceptance of 
production technologies such as all in - all out scheduling and segregated 
early weaning have given the industry the opportunity to refine 
production systems and examine the cost effectiveness of what was once 
considered the norm. The economic challenges of today's pork industry 
do not edlow production practices to be followed simply because they are 
traditional. Each has to be able to demonstrate cost effectiveness on its 
own merit. 
To be able to best assist the pork producer in determining the 
costs and benefits of a PAR vaccination program, the epidemiology of 
toxigenic P. multocida has to be further defined. One of the key steps in 
this process is to identify when the organism transfers to susceptible 
Individuals. 
In vitro culture has been the traditional method to show the 
presence of P. multocida in an individual. One of the problems with this 
technique has been an inconsistency in the ability to recover the 
organism (10,11). 
Following upper respiratory infection with P. multocida, one of the 
following scenarios is likely to happen. First, it is possible the pig could 
mount either a specific immune mediated defense or a nonspecific 
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physical defense that results in the clearing of the organism. Second, 
protection may be formidable enough to decrease the organism numbers, 
but not completely eliminate them. Last, the P. mvltocida may be able to 
establish colonization and multiply. With the first two options, recovery 
of the organism by nasal swabs will probably be unsuccessful. It is 
possible that some cyclical combination of proliferation and partial 
cleciring could occur, also affecting the chances of the organism being 
recovered from carrier animals at any one specific time. These scenarios 
illustrate why inconsistent recoverability may result in false negative 
findings, even though in vitro culture has traditionally been used to 
demonstrate infection. 
Table 3 shows that in this study successful recovery of toxigenic P. 
multocida varied by the day of sampling among rooms and among 
individual pigs. Recovery of the organisms on each sampling day, from 
even the experimentally exposed pigs, was not consistent. Only 6 of the 
10 experimentally exposed pigs yielded recoverable P. multocida during 
the trial. 
Table 2 shows two separately housed, experimentally exposed pigs 
were culture positive on only one day during the trial (number 242, room 
8 on day 14 and number 237, room 9 on day 70). None of the cohorts in 
their isolation rooms were culture positive throughout the trisd. This 
suggests the two culture positive pigs did not clear the organism but had 
suppressed the numbers enough that they were not recoverable, except 
for the one day during the trial. 
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Table 2 also shows transmission to non-experimentally exposed 
pigs was demonstrated by cultiire as early as 7 days post experimental 
exposure (pig 235) with infection continuing as late as day 70 (pig 247). 
This was expected because the cohort pigs were housed, fed and watered 
in common. 
No vaccinated, non-experimentally exposed pigs were culture 
positive on any of the sampling dates suggesting protection from 
treinsmission by vaccination. P. nujltocida bacterin and toxoid vaccinated, 
non-experimentally exposed pigs were statistically less likely to have a 
positive culture on day 7 than were vaccinated and experimentally 
exposed pigs (Table 3). 
Table 4 shov/s the highest rhinitis scores tended to be in the pigs 
that were neither vaccinated nor experimentally exposed. The lowest 
scores tended to be in the pigs that, although they were experimentally 
exposed, were also vaccinated. These pigs however, were statistically the 
same as the pigs that were not vaccinated and experimentally exposed 
(the group that would be expected to have the highest rhinitis scores) so 
the protective effect of vaccination agednst gross PAR lesions is 
questionable. 
Anti-PNTT IgG in the sera (Figure 1) appears to be a good indicator 
of exposure. As could be expected with an experimental exposure 
protocol designed to cause enough nasal mucossd damage to aid 
colonization, those pigs that were experimentally exposed had apparently 
absorbed enough PMT to cause a rapid initial rise In antibody. Pigs not 
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experimentally exposed also had an initial increase, but not as fast or to 
the level of the other pigs, followed by a significant titer rise toward the 
end of the study. 
This serologic profile could support the hypothesis that the non-
experimentally exposed pigs became exposed by transmission within the 
first 21 days. As a group, their anti-PWTr IgG titer then leveled, as 
exposure decreased. Between days 70 and 98 this group appears to be 
again exposed to toxin, causing a significant rise in titer by day 128. This 
exposure is most likely due to either recolonization from a second wave 
of transmission or recrudescence of a lowered level of infection. 
Serum anti-PNTT IgA. does not appear to be a sensitive indicator of 
exposure (Figure 3). There was a tendency for an initial increase in titer 
in the experimentally exposed pigs by day 21, somewhat more delayed 
than the anti-PMT IgG. The experimentally exposed and non-exposed 
pigs showed very similar trends after day 35. 
Although vaccination had no statistical effect on either serum anti-
PMT IgA or IgG, there was a some indication of overall higher anti-PMT 
IgG and lower anti-PMT IgA titers in the vaccinated pigs (Figures 2 and 
4). 
Because of the efforts to ensure nasal samples were collected 
without visual contamination by blood, only the collections done pre-
experimental exposure and on day 35 could be analyzed. This limits the 
value of looking at the nasal anti-PMT titers over time but still gives some 
indication of the movement of the organism within the population. 
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Measuring the nsisal anti-PlVrr IgG supports the supposition that 
experimental exposure causes mucosal irritation that could lead to IgG 
transudation as well as PMT absorption. All pigs received intranasal 
acetic acid according to the experimental protocol. Figure 5 shows those 
pigs that were experimentally exposed had the highest nasal anti-PNTT 
IgG on day 35. The high infectious dose of toxigenic P. multocida given 
to the experimentally exposed pigs may have caused enough inflammation 
to persist to day 35. Because this is only one day post-experimental 
exposure however, it is not possible to tell whether this titer is 
decreasing from a previous higher level or on the rise. 
The nasal anti-PMT IgA for both exposure groups tended to move 
together. The nasal IgA level of the non-experimentally exposed group 
had a greater movement by day 35 than the nasal IgG level of these pigs. 
This would support the argument for transmission of the organism before 
day 35, most probably at a level not great enough to cause extensive 
mucosal damage and transudation of IgG onto the mucosal surface. 
Examining the effect of vaccination on nasal titers (Figure 6) and 
the interaction of vaccination sind exposure (Figures 7 and 8) gives the 
most striking evidence of transmission and the protective effect of 
vaccination. In Figure 6 the non-vaccinated pigs show a greater nasal IgA 
and IgG response than the vaccinated pigs. 
This response must be from infection, the source of which is seen 
in Figures 7 and 8. Those pigs that were not vaccinated and non-
experimentally exposed should be the most susceptible to transmission. 
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The increase in nasal anti-PMT IgA of this group mirrors the increase in 
the not vaccinated and experimentally exposed pigs. Nasal IgA titers can 
be used as an indication of transmission. 
Likewise, the nasal IgA. titers of the vaccinated, non-experimentally 
and experimentally exposed pigs were together, at a low level, on day 35. 
This helps support the contention of vaccination protection from 
trsmsmission seen in Figure 6. 
It appears there are different abilities of aU of these measurements 
to detect transmission. Turbinate damage is the least specific indication 
and does not correspond well with other methods. The environment of 
these pigs in the research facilities was, subjectively, better than that of 
pigs in most commercial units. Singling out the environment as a cause 
of gross lesions does not seen reasonable. The possibility does exist some 
other infectious agent not accounted for in this study caused the lack of 
gross lesion similarity between treatment groups. 
If absorption of toxin can be assumed to take place, sera anti-PMT 
IgG appears to be a better indicator of exposure than sera anti-PMT IgA. 
In the nasal passages, measuring anti-PMT IgA is a good indicator of 
exposure from transmission. Nassil IgG titers were too dependent on a 
deeper, more inflammatory infection causing transudation to be a reliable 
indication of transmission. 
Culture results and serological and mucosal assay do support each 
other. The exposed pigs were more likely to be culture positive on day 7 
and to have a high anti-PMT IgG titer by that day. Antibody assays and 
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culture results suggested transmission had occurred, especially in non-
vaccinated pigs. 
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TO STUDY TOXIGENIC PASTEURELLA MULTOCIDA 
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Abstract 
Restriction endonuclease analysis (REA), serotyping, and 
toxigenicity were used to follow transmission of a toxigenic Pasteurella 
multocida strain P4148, among commingled feeder pigs. Twenty pigs 
(14 to 18 kg) were nasal swabbed. Swabs were cultured, and cultures 
were evaluated for BordeteJla bronchiseptica and toxigenic Pasteurella 
multocida status; bacterial cultures from nasal swabs of all 20 pigs were 
negative for these pathogens. Pigs were randomly divided into two 
groups, both groups received an intranasal inoculation of a sterile 
toxigenic B. bronchiseptica sonicate; one group (designated as exposed) 
was inoculated with a toxigenic P. multocida 48 hours later. The 
remaining group (designated as nonexposed) was not inoculated with a 
toxigenic P. multocida. Characterization of isolates from nasal swab 
cultures demonstrated P. multocida transmission from the exposed to 
nonexposed pigs. Transmission of toxigenic P. multocida strain P4148 
was confirmed by REA, serotyping, and P. multocida toxin ELISA. 
Background nontoxigenic P. multocida strains were recovered from the 
pigs and these strains were the same somatic type as strain P4148. The 
background nontoxigenic strains were easily differentiated from strain 
126 
P4148 by REA and toxigenicity. REA confirmed that the profile of each 
toxigenic isolate recovered from a nasal swab was identical to the profile 
of P4148. Other toxigenic P. midtocida were not isolated or identified 
from any of the 20 pigs. REA is a useftil epidemiological tool that, when 
used with serotyping and toxigenicity assay, can further differentiate P. 
multocida strains during clinical trials. 
bitroduction 
Swine progressive atrophic rhinitis (PAR) is a specific disease entity 
caused by infection with toxigenic Pasteurella multocida (18). The 
clinical syndrome associated with PAR is of considerable economic 
importance to the swine industry (4, 9, 15). Post mortem examinations 
conducted at slaughter plants have shown that up to two-thirds of the 
marketable age swine in the United States show signs of turbinate 
atrophy, one of the overt manifestations of PAR (15). 
The etiologic agent of PAR is toxigenic P. nvultocida. Colonization 
and toxigenicity are the most important P. multocida virulence 
determinants (14). Because nontoxigenic strciins of P. multocida are 
normal residents on the nasal mucosa of healthy pigs (16), the 
determination of toxigenicity is central in reaching a PAR diagnosis. 
Animal models (6), cytotoxicity assays (6), colony blot immunoassays (20). 
ELISA techniques (8) and DNA probes (19) have been used to detect the 
presence of or potential for P. multocida toxin in cultures. 
Capsular and somatic serotyping, phage typing and restriction 
endonuclease assay (REA) have been used together with toxigenicity 
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assays to study the epidemiology of PAR and determine a likely period of 
toxigenic P. multocida exposure. Once thought to be transmitted 
principally from sow to piglets during the first weeks of life, there is 
increasing evidence toxigenic P. midtocida initially infects a few nursing 
pigs which become carriers. Primary herd transmission then occurs 
among cohort pigs post weaning (17, 23). 
Recently REA has been used to allow greater differentiation of P. 
midtocida strains than that afforded by phenotyping techniques (10, 22, 
23, 24). Cross-sectional observational studies support the use of REA in 
combination with classical capsular and somatic typing as an 
epidemiologic tool to provide information regarding P. midtocida 
identification. Isolates of identical capsular and somatic types can be 
further classified by REA pattern. 
REA has furthered the epidemiological study of pneumonic 
pasteurellosis, however, only one study has addressed the relationship 
among PAR, capsular and somatic type, toxigenicity and REA (10). Data 
from that study suggest one REIA pattern can come from identical 
capsular type strains that differed in toxigenicity based on the guinea pig 
dermonecrosis assay. 
Transmission studies in field and experimental situations have 
demonstrated an inconsistency in the ability to sequentially and 
quantitatively isolate toxigenic P. midtocida when the identifying criteria 
are capsular type and toxigenicity (2, 5, 12, 13 ). It could not be 
determined if this inability to consistently recover the organism was due 
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to clearance followed by reinfection, persistent infection with numbers 
too low to recover, errors in sampling and culture technique or a change 
in the bacteria, stopping toxin production and thus detection. 
The objective of this experiment was to follow transmission, by REA 
and phenotypic characteristics, of an inoculated toxigenic P. multocida 
among cohort pigs in a clinical trial. REA, serotyping and an ELISA 
designed to detect presence of toxin were used to determine whether 
toxigenic P. multocida can escape detection upon isolation and 
subculture. 
Materials and Methods 
Toxigenic B. bronchiseptica (strain P-4609) and toxigenic P. 
multocixia (Serotype D:3, strain P4148 - referred to as the reference 
strain) were supplied by the USDA National Animal Disease Laboratory, 
Ames, Iowa, Toxigenicity of the P. midtocijda was confirmed by ELISA 
prior to beginning the project. 
Twenty pigs ranging in weight from 14 to 18 kg were randomly 
assigned, five pigs to each of four rooms. The rooms were designed for 
isolation with separate feeders, water outlets, ventilation and waste 
disposal. All pigs were clinically normal and negative for B. 
bronchiseptica and toxigenic P. multocida by nasal swab culture. They 
were fed, ad libitum, a corn-soybean based diet without antibiotics. 
The pigs in each room, after 14 day acclimation, were randomly 
divided into exposed and nonexposed groups. Two pigs in two rooms 
and three pigs in each of the remaining rooms were exposed. The other 
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pigs in all rooms were not exposed. 
All pigs were held tn an upright position and inoculated via flexible, 
polyethylene catheter attached to a 3 ml. sjnringe. A sterile sonicate of a 
toxigenic B. bronchiseptica was instilled in the nasal passages of aJl pigs. 
Forty-eight hours later, 1 ml. of a live culture suspension of toxigenic P. 
multocida , diluted in phosphate buffered saline to a density equivalent to 
that of a McFarland 1 nephelometer standard, Wcis instilled in each nasal 
passage of those pigs assigned to the exposed group. Pigs in the 
nonexposed group received sterile culture media, the same as that used 
to grow the PasteureUa. midtocuia. Sonicates and cultures were prepared 
according to the protocol of Ackermann, Rimler and Thurston (1). 
After wiping the external surface of the nose with an individual 
gauze sponge, a cotton-tipped miniswab^ was used to sample the conchae 
of each nostril. The trcinsport media vial with each swab was not broken 
following collection as the swabs were submitted for culture immediately 
after sample collection. Samples were collected for culture and analysis 
immediately preinoculation and on days 3, 7, 14, 21 and 28 
postinoculation. 
Each swab was immersed in 2.0 ml of sterile water and mixed by 
vortex mixer. On each of a 5% sheep blood agar plate and a plate 
containing a selective medium using a Columbia blood agar base with 
neomycin and bacitracin (12, 13) 200 p.1 were then placed. Each plate 
a Mini-Tip Culturette®, Becton Dickinson Microbiology Systems, 
Cockeysville, Marylsind 
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was streaked for isolation. 
After 48 hours of aerobic incubation at 37°C, up to five isolated 
colonies visually identified as possible P. midtocida on each plate were 
given coded identification. Each colony was then transferred to a 5% 
sheep blood agar plate and also into dextrose, sucrose, maltose, mannitol, 
lactose, indole and urea media. Those strains which produced reactions 
typical of P. multocida were then transferred firom the 5% sheep blood 
agar plate to a BHI slant for REA. The remaining colonies on the 5% 
sheep blood agar plate were used for ELISA determination of toxin 
production. 
Toxigenicity determination, serotyping and REA 
Toxin production was detected using a commercially available ELISA 
kit^ as directed by the manufacturer. Each assay was done in duplicate. 
The coded BHI slants of P. midtocida were submitted for capsular 
and somatic typing and REA. Associations of isolates could not be 
determined without knowledge of the coding system. Capsular typing 
was performed by the hyaluronidase inhibition assay of Carter (3). 
Somatic antigen type was determined by the method of Heddleston, et al. 
(11) Chromosomal DNA isolation, restriction endonuclease digestion 
using Hhalc, electrophoresis and photography were performed by the 
methods of Wilson, et al. (22) 
Statistical einalysis was performed using the Chi squared test. 
b DAKO PMT ELISA®, DAKO Corporation, Carpinteria, California 
c Life Technologies, Inc., Gaithersburg, Maryland 
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Results 
Culture and toxigeniclty 
Table 1 details the results of the culture and toxigeniclty assay. 
Toxigenic P. multocida was isolated from nasal swabs of exposed and 
nonexposed pigs as early as three days post exposure. Recovery of a 
toxigenic isolate occurred from exposed pigs in rooms 1, 2 and 4. 
Toxigenic P. multocida was recovered from at least one nonexposed pig 
in rooms 1 and 4. No toxigenic P. multocida was recovered from exposed 
or nonexposed pigs in room 3. Consistent recovery of P. multocida was 
shown in only one pig, pig number 2, which was exposed and housed in 
room 1. 
Recoverability of toxigenic P. multocida varied greatly (Table 2). Of 
60 exposed pig samples, 15 had a positive reaction for P. multocida toxin 
cifter culture. Recoverability from exposed pigs varied between rooms 
(Table 2) and, over time, within rooms (Table 1). 
Toxigenic P. multocida was recovered from exposed and 
nonexposed pigs. Table 3 identifies the pigs from which a P. multocida 
toxin positive culture was grown during the course at the project. Rooms 
I and 4 each contained 1 nonexposed pig from which a toxin positive 
culture was obtained. There was no significant difference between the 
nimiber of exposed pigs and the number of nonexposed pigs yielding P. 
multocida toxin positive cultures (Table 3). 
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TABLE 1. Culture isolation and toxigenicity results. 
Culture, by day 
Pig 
ID 
Expo­
sure Room 
Pre-
Exp 3 7 14 21 28 35 
1 Not^ 1 C o d  - . tJl Bi Bi. B2^ Bi - - -.Bi 
2 Exp^ 1 - +. Bi, B2 + + + + 
3 Exp 1 - + + - + + + 
4 Not 1 - - + + - - + 
5 Exp 1 - + - - - - -
6 Not 2 - - - - - - -
7 Exp 2 - - - - - - -
8 Not 2 - - - - - - -
9 Exp 2 - - - - - - -
10 Exp 2 - - + - - - -
11 Not 3 - - - - - - -
12 Not 3 - - - - - - -
13 Exp 3 - - - - - - -
14 Exp 3 - - - - - - -
15 Not 3 - - - - - - -
16 Not 4 - - - - - - -
17 Not 4 - + + - - + + 
18 Not 4 - - - - - - -
19 Exp 4 - - - - - - -
20 Exp 4 - - + + - - -
^ Not exposed 
^ Exposed 
^ Culture P. multocida toxin negative 
^ Background REA type 1. nontoxigenic P. multocida 
^ Culture P. multocida toxin positive 
^ Background REA type 2, nontoxigenic P. multocida 
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TABLE 2. Number of nasal swab prlmcuy cultures positive for P. 
multocida toxin. 
Room Exposed Pigs Not Exposed Pigs 
1 12 / 18^ 3 / 12® 
2 1 / 18 0 / 1 2  
3 0 / 1 2  0 / 1 8  
4 2 / 1 2  4 / 1 8  
Total 15 / 60'' 7 / 60^^ 
Values with same superscripts are significantly different, p <0.1 
TABLE 3. Number of pigs yielding culture of P. multocida which 
produced toxin 
Room Exposed Pigs Not Exposed Pigs 
1 3 / 3 ®  1 / 2 ®  
2 1 / 3  0 / 2  
3 0 / 2  0 / 3  
4 1 / 2  1 / 3  
Total 5 / 10^ 4 / 10^ 
Values with same superscripts are significantly different, p < 0.1 
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Restriction endonuclease analysis and phenotypic typing 
Eighty-six colonies from 27 nasal swab cultures were identified as P. 
midtocida by visual and biochemical criteria. All were negative for 
capsular type A using Carter's hyaluronidase capsular typing test. Eighty-
four of the 86 colonies were found to belong to somatic type 3 when 
referenced by the Heddleston somatic typing assay. Two colonies were 
somatically untypable. The P. midtocida reference strain was also somatic 
type 3 and negative to capsular type A. 
Fifty-one of the 86 colonies were toxigenic and found to have an 
REA pattern identical to the inoculated reference strain P4148 (Figure 1, 
lane 1). Included in these 51 colonies were isolates from each of the two 
nonexposed pigs that yielded toxin positive cultures. 
Thirty-three of the 35 colonies were nontoxigenic and possessed 
the REA pattern shown in Figure 1, lane 2 (P. midtocida background type 
1). The remaining two colonies were nontoxigenic and found to have the 
REA pattern of Figure 1, lane 3 (P. midtocida background type 2). All 35 
colonies with REA patterns differing from the reference strain were 
isolates from two pigs, nimibers 1 and 2, in room 1. 
Background P. multocida (profile type 1) was isolated from pig 
numbers 1 and 2 before the date of exposure. The identical isolate was 
recovered from pig 1 on days 3, 7. 14 and 35 and from pig 2 on day 7 
(Table 1). Backgroimd P. multocida (profile type 2) was isolated from pig 
numbers 1 and 2 on day 7 (Table 1). No other nontoxigenic P. midtocida 
was recovered. 
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FIG 1. Agarose gel DNA fingerprint profiles of representative P. 
multocida colonies. Lanes: 1. Hhal profile of the inoculated 
toxigenic P. multocida reference strain and all recovered 
toxigenic isolates; 2, Hhal profile of the nontoxigenic 
background type 1 P. multocida; 3, Hhal profile of the 
nontoxigenic background type 2 P. multocida: 4, DNA from 
lambda phage digested with Hind III. 
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Discussion 
REA has been used in observational cross section studies in which 
transmission has been suggested (10, 22, 23, 24). In this project, 
toxigenic P. multocuia trcinsmission was implied by phenotypic 
characteristics (capsular and somatic typing and toxigenicity) and 
confirmed by RE^. 
During initial epidemiological studies of P. multocida, transmission 
was defined by recovery of a capsular and somatic type P. multocida that 
was the same as the inoculated strain. The discovery of the P. multocida 
toxin gave an additional tool with which to differentiate strains. It is 
possible for separate isolates to have identical capsular and somatic types 
but different toxigenic capabilities. RE^ gives additional support to 
epidemiological studies by further differentiating isolates which are 
similar in other ways. 
Table 1 shows the inconsistent recoverability of P. multocida from 
pigs exposed to the organism. This was not surprising and agrees with 
the results of previous studies (1, 3, 5, 11). 
A recovery pattern such as this is of concern when sampling pigs in 
a clinical setting or verifying toxigenic P. multocida free status prior to a 
clinical study. Using only phenotypic characteristics to detect 
trsmsmission may lead to a false sense of security. Defining a positive 
result as detection of P. multocida toxin, three exposed pigs were culture 
negative on day three, then positive on day seven. Pig number 17 would 
have been considered negative had initial samples been taken on day 14 
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or day 21 fTable 1). Had this pig then been assigned to a toxigenic P. 
multocida free group used to monitor transmission, transmission would 
have mistakenly appeared to have occurred when the pig cultured 
positive on day 28. Using REA, the toxigenic isolates recovered during 
this experiment, although recovered on an intermittent basis, were 
confirmed to be identical to that of the inoculated reference strain. 
Determination of toxigenicity alone could not have differentiated a 
backgroimd toxigenic strain, that was initially not detected, from the 
inoculated toxigenic strain. 
Multiple colonies from the primary nasal swab cultures were used to 
decrease the likelihood of not sampling genotypically unique colonies 
that may be visusilly identical. Each group of up to five subcultured 
colonies coming from a primary nasal culture was found to have identical 
capsular and somatic types, toxigenicity and RE^ fingerprint pattern. 
Previous studies have focused on pneumonic pasteurellosis without 
correlating toxigenicity to REA pattern (23, 24). Harel, et al., reported 
identical DNA fingerprints for toxin positive and toxin negative isolates 
(10). The toxA gene, encoding for toxin production, has been identified 
as chromosomal (19). As such, a DNA fingerprint of a toxigenic isolate 
may differ from that of a nontoxigenic isolate, if the lack of toxigenicity is 
due to toxA deletion. Differentiation between toxigenic and nontoxigenic 
P. multocida strains by REA was shown in this study. Using Hhal, the 
nontoxigenic background P. multocida strains were easily distinguishable 
from the inoculated toxigenic reference strain. 
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Toxigenicity determinatioii method and restriction endonuclease 
selection may affect results. Hhcd digestion results in distinct fingerprint 
profiles easily distinguishable with the naked eye. Additionally, this study 
used ELISA for toxin detection rather than a less sensitive (7), less 
reproducible and more subjective (21) bioassay. 
The only toxigenic strsiin isolated was the inoculated reference 
strain. It produced a unique DNA fingerprint pattern distinguishable 
from the recovered nontoxigenic background strains. To determine a 
range and comparison of toxigenic and nontoxigenic P. multocida REA 
fingerprints surveying herds affected with clinical progressive atrophic 
rhinitis has yet to be done. 
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VI. GENERAL CONCLUSION 
As the pork production industry has evolved, £Lnimai production has 
become more concentrated. The desire to decrease labor and land 
appropriated to production while maximizing efficiency has led to greater 
populations of pigs being housed in spaces small enough to not limit 
growth and production. This increase in animal concentration also has 
created an increase in opportunity for transmission of diseases. 
Economically preventing diseases from affecting their animal's 
production has been a goal of farmers since they first started to 
domesticate animals. An early way to prevent disease was to remove the 
diseased animals and decrease the concentration of the herd. Modem 
pork producers may not have this option. Instead, they may need to rely 
on decreasing exposure, decreasing infection, or stimulating immunity. 
The industry is starting to leam how to reduce exposure without 
decreasing herd concentration. Advances in environmental control have 
helped decrease exposure by reducing stresses that contribute to 
shedding and by reducing time of contact between pathogens and 
animals. Management techniques to reduce horizontal or vertical 
transmission are becoming industry standards. 
One method for the pork producer to reduce transmission among 
pigs is to increase the level of immunity. To do this, pork producers 
routinely use vaccination as a management technique. It is generally held 
that for most situations the higher the antibody titer the greater the 
protection against transmission and the effects of the pathogen. Any 
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cost-effective improvement in the vaccination process that would result 
in increased immunity would be adopted by the pork production industry. 
In these experiments, beta-hydroxy beta-methyl butyrate (HMB) 
was used in an attempt to increase the immime reaction to vaccination. 
Some dose response effect of HMB on antibody production was seen. 
Supplementation with two grams of HMB once daily caused a response to 
vaccination that tended to be higher than that in either those given ten 
grams once daily or controls not receiving HMB. This and the HMB 
effect on class specific amtibody production were variable enough to 
warrant further study to better define how HMB could be used to mediate 
an immune response. 
For other management techniques to be most useful in decreasing 
transmission, the epidemiology of the particular organism of interest 
must be understood. Basic to this imderstanding is a method to reliably 
detect transmission. 
One classic technique of inferring transmission is by showing 
seroconversion, a biological indication of antigen exposure to a 
competent immune system. For it to be an effective Indicator, the 
organism must be in contact with systemic immimocj^es that are capable 
of producing an antibody response. There must also be enough time for 
the immunocytes to produce antibodies in detectable quantities. 
For bacterial respiratory infections, the first exposure to the 
organism comes from contact Avith the body's mucosal surfaces. With 
toxigenic P. multocida and the upper respiratory tract, the opportunity 
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for toxin exposure to both the mucosal and systemic immune systems 
happens after absorption of the toxin. It is not unreasonable to expect 
antibody production by both systems. The nature of the reaction, the 
period within which it occurs and its amount could show exposure from 
transmission. 
In these studies, this was the case. Serum antl-PMT IgG was an 
effective indicator of transmission by day 21 after mingling with 
experimentally exposed pigs. A second wave of exposure between days 
70 and 98 was also detected serologically. 
Antl-PMT IgA on the nasal mucosal surface also could be used to 
show transmission. Because of constraints from collection, the earliest 
sample for assay was from day 35 post-mixing with experimentally 
exposed pigs. This leaves open the question of how early during an 
infection mucosal IgA could be used to show transmission, but it does 
show the ability of assay for class specific antibody from the mucosal 
surface to indicate exposure. Further experimentation is needed to 
define the time needed for detectable antibody production on the nasal 
surface. 
Another method of showing trcinsmlssion is by recovery of the 
organism. With P. midtocidjo, recovery from even experimentally exposed 
individuals is unreliable. It is not known whether this is a factor of the 
sampling technique, at least partial clearance of the organism with 
reinfection or recrudescence, or recovery of different P. multocida 
organisms with similar phenotypic characteristics. The inconsistent 
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recovery brings into question the reliability of this technique for 
diagnosis, especially on an individual animal basis. Even when using this 
on a herd basis, one has to be careful not to underestimate prevalence 
based on one sampling. 
With experimentally inoculated animals, the same problems with 
unreliable recovery exist. Because of this, as with recovery from naturally 
exposed animals, using culture for detection of transmission should be 
equally suspect. Chance recovery of a previously undetected strain of 
bacteria that is phenotypically identical to an inoculated strain would 
interfere with data iaterpretation and lead to false conclusions about 
transmission and prevalence. Restriction endonuclease analysis of the 
bacterial DNA was used to show that, at least under the conditions of this 
experiment, recovery of the organism was a positive indication of the 
transmission of the inoculated strain. 
Finally, while helping to answer some questions about the 
epidemiology of toxigenic type D P. multocida, this research also 
demonstrated a technique that could have longer reaching effects. 
Whether bacterial or viral, a pig first contacts most pathogens on a 
mucosal surface. This gives the mucosal surface the first opportvmity to 
preclude infection and prevent its economic effects. This is why it is so 
important to understand pathogen interactions with this immime system. 
Sampling mucosal surfaces directly, without dilution or 
contamination from washing and flushing gives the opportunity to detect 
exposure cind immune reaction in a very site specific marmer. This 
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technique could be applied to study the epidemiology of many pathogens. 
Salmonella may be contacted through the nasal passages as a pig sniffs 
and roots in a contaminated environment. Perhaps by similar sample 
collection and ELISA use, a greater understanding of salmonella exposure 
and immune interaction could be gained. Systems of salmonella control 
and elimination that could be helpful in food safety initiatives could then 
be developed. 
Viral infections such as Porcine Respiratory and Reproductive 
Syndrome (PRRS) are greatly affecting the pork production industry. 
One possible portal of entry into the body and site of viral replication is 
the nasal mucosa. Using similar methods, perhaps we could gain a better 
understanding of the role mucosal exposure and immune reaction plays 
in the pathogenesis of this syndrome. 
Whatever pathogen is studied, if it causes a measurable effect on the 
profitability of the pork producer and it is transmitted by contact with a 
mucosal surface, these techniques may be helpful in defining its 
epidemiology. Further study should help refine their reliability and 
usefulness. 
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APPENDIX 
Table 1. Sera HMB levels (micromolar) in gilts fed HMB top-dressed 
on feed once daily (n = 12 for each HMB treatment). 
Days 
Grams of HMB fed per day 
0 2 10 
-38 3.5 3.3 4.7 
-28 3.3 45.3 149.5 
-14 4.8 30.8 136.9 
-7 3.4 42.4 131.1 
1 4.1 65.4 105.6 
7 7.4 24.8 149.3 
14 4.6 21.8 140.4 
21 5.2 17.7 102.1 
Ave SEM=15; all values are significantly different across treatments at 
p<0.01 
Table 2. Anti-tetanus sera titers (log base 2) of gilts fed varying levels 
of HMB once daily (titer (n)). 
Grams of HMB fed per day 
0 2 10 
-38 7.5 (10) 7.5 (11) 7.5 (11) 
-28 11.6 (10) 13.0^ (10) 10.8^ (11) 
-14 ii.g"" (7) A A 14.4 (7) 10.8® (9) 
-7 11.1 (10) 11.9 (10) 10.8 (10) 
1 10.3^ (10) 11.6^ (10) 11.3 (8) 
7 9.7 (10) 10.9 (11) 10.3 (9) 
14 9.0 (10) 9.9 (11) 10.0 (8) 
21 10.9^° (6) 8.3® (7) 7.6^ (5) 
Ave SEM=0.81 ; For like letters across rows, p<0.10. 
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Table 3. Antl-pseudorabies sera titers (log base 2) of gilts fed vaiylng 
levels of HMB once dally (titer (n)). 
Grams of HMB fed per day 
Days 0 2 10 
-38 1.64 (12) 1.64 (12) 1.64 (12) 
-28 2.50^ (4) 3.34^ (3) 2.57 (4) 
-14 3.91 (12) 3.35 (12) 2.99 (12) 
-7 2.92® (4) 3.65° (5) 2.95 (6) 
1 1.94 (8) 2.24^" (7) 1.45'' (7) 
7 2.92 (12) 3.29 (11) 3.08 (11) 
14 2.49 (11) 2.80 (10) 2.62 (9) 
21 2.60 (11) 2.29 (11) 2.32 (9) 
Ave SEM = 0.5; For like letters across rows, p<0.10. 
Table 4. Sera IgA. titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed vars^ing levels of HMB once daily, 
day 1 post-farrowing (titer (n)). 
VACC 
HMB (gms per day) 
0 2 10 
1.58'' (5) 0.70^ (6) 0.23® (2) 
4.79"^°" (1) 2.48 (1) 1.96° (1) 
MEAN 
yes ^ " 3° 0.84'^ 
no . 9-"  . " 3.08'' 
MEAN 3.18 1.59 1.09 
Ave SEM=1.1; ^®p<0.05, ''•°p<0.1 
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Table 5. Sera IgA. titers (log base 2 and corrected by subtraction of 
baseline titer) in ^ts fed varying levels of HMB once daily, 
day 7 post-farrowing (titer (n)). 
HMB (gms per day) 
0 2 10 MEAN 
yes 2.69 0.94 2.48 2.04 
no 1.03 0.70 0.12 0.62 
MEAN 1.86 0.82 1.30 
Ave SEM=1.39 
Table 6. Sera IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily. 
HMB (gms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
2.45 (3)^ -0.64 (3)^° 1.83 [3f 1.21 
-0.58 (1) -0.19 (1) na 
-0.38 
MEAN 0.93 -0.41 1.83 
Ave SEM=0.95; For like letters, p<0.10 
Table 7. Sera IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in ^ts fed varying levels of HMB once daily, 
day 21 post-farrowing (titer (n)). 
HMB (gms per day) 
VACC 
0 2 10 MEAN 
yes 0.42° (3) 0.39^ (5) 0.40'' (2) 0.40'' 
no 3.85°"°(1) na -0.10° (2) 1.88'^ 
MEAN 2.14^° 0.39^ 0.15° 
Ave SEM=0.36; For like letters p<0.05. 
149 
Table 8. Sera IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in ^ts fed varjong levels of HMB once daily. 
HMB Cgms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
-0.06 (7) 
0.67 (2) 
0.57 (6) 
1.46 (I) 
0.29 (2) 
0.57 (1) 
0.27 
0.90 
MEAN 0.31 1.01 0.43 
Ave SEM=0.71 
Table 9. Sera IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in ^ts fed varying levels of HMB once daily, 
day 7 post-farrowing (titer (n)). 
HMB (gms per day) 
0 2 10 MEAN 
0.61 1.08 0.76 0.82 
0.76 (1) -0.69 (1) 0.76 (2) 0.28 
MEAN 0.69 0.19 0.76 
Ave SEM=0.99 
Table 10. Sera IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily. 
HMB (gms per day) 
MEAN 0 2 10 
-0.08 (4) 0.54 0.37 (2) 0.28 
VACC 
no 1.66 (1) na 0.58 (2) 1.12 
MEAN 0.79 0.54 0.48 
Ave SEM=0.77 
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Table 11. Nasal IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily. 
HBCB [^ms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
0.55 (4) 
na 
0.03 (4) 
0.01 (3) 
0.51 (2) 
-0.02 (1) 
0.362 
0.003 
MEAN 0.55 0.02 0.24 
Ave SEM=0.57 
Table 12. Nasal IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily, 
HMB (gms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
1.03 (3) 
0.87 (2) 
0.43 (6) 
0.75 (1) 
0.96 (4) 
1.10 (2) 
0.81 
0.91 
MEAN 0.95 0.59 1.03 
Ave SEM=0.60 
Table 13. Nasal IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily, 
day 14 post-farrowing (titer (n)). 
VACC 
HMB (gms per day) 
0 2 10 MEAN 
yes 0.02''(5) 0.56®(4) 0.32"" (4) 0.30 
no -0.16'' (1) 3.06^®''(2) -0.11® (3) 0.93 
MEAN -0.07 1.81 0.10 
Ave SEM=1.09; '^®p<0.10, ^<0-05 
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Table 14. Nasal IgA titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once dgiily. 
HMB (gms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
2.31 (4) 
-0.19 (1) 
0.63 (4) 
na 
1.98 (2) 
0.85 (2) 
1.64 
0.33 
MEAN 1.06 0.63 1.42 
Ave SEM=L99 
Table 15. Nasal IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily, 
day 1 post-farrowing (titer (n)). 
VACC 
HMB (gms per day) 
0 2 10 MEAN 
yes 1.63 (4) 0.66 (4) 1.26 (2) 1.18 
no na 0.36 (3) 0.60 (1) 0.48 
MEAN 1.63 0.51 0.93 
Ave SEM=0.81 
Table 16. Nasal IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily. 
HMB (gms per day) 
0 2 10 MEAN 
yes 
VACC 
no 
0.49 (3) 
0.04 (1) 
0.14 (6) 
0.02 (1) 
0.16 (4) 
0.40 (2) 
0.26 
0.15 
MEAN 0.27 0.08 0.28 
Ave SEM=0.33 
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Table 17. Nasal IgG titers (log base 2 and corrected by subtraction of 
baseline titer) in gilts fed varying levels of HMB once daily. 
HMB (gms per day) 
MEAN 0 2 10 
yes o
 
b
 
CO
 > (5) 0.62^ (5) 0.59 (4) 0.41 
VACC 
no 0.54 (1) 0.54 (2) 0.44 (3) 0.51 
MEAN 0.28 0.48 0.51 
Ave SEM=0.34; ^p<0.10 
Table 18. Nasal IgG titers (log base 2 and corrected by subtraction of 
bciseline titer) in gilts fed varying levels of HMB once daily. 
HMB (gms per day) 
MEAN 0 2 10 
yes 0.21 (4) 0.32 (4) 0.16 (2) 0.23 
VACC 
no -0.09 (1) na 0.57 (2) 0.24 
MEAN 0.06 0.32 0.36 
Ave SEM=0.31 
Table 19. Sera anti-PMT IgG (log base 2), Day 7 post-
experimental toxigenic P. nmltocida exposure 
in 6 wk old pigs 
Exposure 
yes no MEAN 
yes 9.92 8.24 9.08 
no 8.99 8.07 8.53 
MEAN 9.46 8.16 
Ave SEM = 0.76; p for treatment interaction = 0.62 
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Table 20. Sera anti-PMT IgG (log base 2), Day 21 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
^cposure 
yes no MEAN 
yes 9.14 9.13 9.13 
no 8.10 8.96 8.53 
MEAN 8.62 9.04 
Ave SEM = 0.42; p for treatment interaction = 0.30 
Table 21. Sera anti-PMT IgG Qog base 2), Day 35 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^zposiire 
yes no MEAN 
yes 9.23 8.54 8.88 
no 8.72 8.56 8.64 
MEAN 8.98 8.55 
Ave SEM = 0.49; p for treatment interaction = 0.58 
Table 22. Sera 8inti-PMT IgG Qog base 2), Day 70 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^cposure 
yes no MEAN 
yes 9.58 8.72 9.15 
no 9.06 8.12 8.59 
MEAN 9.32 8.42 
Ave SEM = 0.34; p for treatment interaction = 0.90 
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Table 23. Sera anti-PMT IgG (log base 2), Day 98 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^osure 
yes no MEAN 
yes 10.57 9.64 10.1 
no 8.82 8.75 8.78 
MEAN 9.70 9.20 
Ave SEM = 0.75; p for treatment interaction = 0.45 
Table 24, Sera anti-PMT IgG (log base 2), Day 124 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
Exposure 
yes no MEAN 
yes 9.11 10.08 9.60 
no 9.83 10.15 9.99 
MEAN 9.47 10.10 
Ave SEM = 0.36; p for treatment interaction = 0.39 
Table 25. Sera anti-PWrr IgA (log base 2), Day 7 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
Ezp Exposure 
yes no MEAN 
yes 3.54 3.79 3.66 
no 4.57 2.58 3.58 
MEAN 4.06 3.18 
Ave SEM = 1.73: p for treatment interaction = 0.54 
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Table 26. Sera anti-PMT IgA. (log base 2), Day 21 post-
experimental toxigenic P. multocida exposxire 
in 6 wk old pigs 
^cposure 
yes no MEAN 
yes 4.10 3.47 3.78 
no 5.54 2.34 3.94 
MEAN 4.82 2.90 
Ave SEM = 0.92; p for treatment interaction = 0.26 
Table 27. Sera anti-PMT IgA (log base 2), Day 35 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^xposure 
yes no MEAN 
yes 2.81 1.30 2.06 
no 4.74 2.63 3.68 
MEAN 3.78 1.96 
Ave SEM = 3.07; p for treatment interaction = 0.94 
Table 28. Sera anti-PMT IgA (log base 2), Day 70 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^zposure 
yes no MEAN 
yes 2.19 2.90 2.54 
no 3.66 3.85 3.76 
MEAN 2.92 3.38 
Ave SEM = 1.64; p for treatment interaction = 0.88 
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Table 29. Sera sintl-PMT IgA. (log base 2). Day 124 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
E^zposure 
yes no MEAN 
yes 3.47 2.77 3.12 
no 3.92 5.60 4.76 
MEAN 3.70 4.18 
Ave SEM = 0.53; p for treatment interaction = 0.23 
Table 30. Nasal anti-PMT IgG (log base 2), Day 35 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
Exposure 
yes no MEAN 
yes 1.37 
-0.20"" 0.58 
no 3.35"" 1.36 2.35 
MEAN 2.36 0.58 
Ave SEM = 1.34; p for interaction = 0.88; *p = 0.08 
Table 31. Nasal Etnti-PRTT IgA (log base 2), Day 35 post-
experimental toxigenic P. multocida exposure 
in 6 wk old pigs 
Exposure 
yes no MEAN 
yes -0.11 0.45 0.34 
no 1.91 2.43 2.17 
0.90 1.44 
Ave SEM = 1.16; p for interaction = 0.98 
